A Phase 1/2 interventional study of AltSonflex1-2-3 High Dose and AltSonflex1-2-3 Medium Dose in Diarrhoea, sponsored by GlaxoSmithKline. Completed at 2 sites in 2 countries. Open to participants aged 9 Months to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-22.
Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Diarrhea with a site in Belgium — 1 open to participants now, 1 under way, none of them phase 3. Diarrhea · Belgium.
Among the 14 studies in Diarrhea with a site in Belgium, this one has the largest enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 1/2, and was the 11th registered.
879 studies on the registry are indexed under Diarrhea; 77 are open to participants now.
Browse Diarrhea studies →1 of the 14 studies in Diarrhea with a site in Belgium is open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Belgium, United States, Canada and 7 more countries
Ages 18–75
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 45 Diarrhea studies recruiting now, 21 (47%) set no upper age limit and 22 (49%) stop at 75 or younger; 19 take children under 18; 15 take healthy volunteers.
This study: 9 Months to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4
First in 2004; this study’s year is marked. 2 started in 2021.
This study's enrollment of 551 is above the median of 138 across 739 interventional studies indexed under Diarrhea.
Median enrollment 284 across the 12 interventional studies, 243 across the 2 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 6 studies filed under Diarrhea — fewer than ten, so there is no comparison to draw.
1 of the studies in Diarrhea with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07545759Eli Lilly and CompanyA Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Diarrhea with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the current clinical study was to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S. sonnei and S. flexneri serotypes 1b, 2a, and 3a. The vaccine was first administered to adults 18 to 50 years of age in Europe. Subsequently, the vaccine was administered to a shigellosis-endemic population in Africa, first to adults 18 to 50 years of age, then to children 24 to 59 months of age, and finally to infants 9 months of age. Infants also received a third vaccination. Three different doses of the vaccine [low, medium, and high amounts of antigen] were evaluated using an age de-escalation approach (from the least vulnerable adult population to the most vulnerable paediatric population). The results of this study allowed the selection of the most appropriate dose for further vaccine development in infants 9 months of age, which was the main target age group for this vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants:
Adults 18 to 50 years of age:
Female participants of childbearing potential may be enrolled in the study, if the participant:
- has practiced adequate for 1 month prior to study intervention administration, and
- has a negative pregnancy test on the day of study intervention administration, and
Children 24 to 59 months of age:
Infants 9 months of age:
Exclusion Criteria:
All participants:
Exclusion due to travel or occupation was applicable only to adults 18 to 50 years of age in Europe (Stage 1).
The participant could still be enrolled into the study at a time when the acute disease and/or fever had resolved.
Use of herbs and traditional treatments was not considered an exclusion criterion.
Vaccines allowed by the Protocol included flu and COVID-19 vaccines in all participants and EPI vaccines in children and infants.
*In case of emergency mass vaccination, the time period above could be reduced.
Adults 18 to 50 years of age:
Adults 18 to 50 years of age and children 24 to 59 months of age:
Children 24 to 59 months of age and infants 9 months of age:
Infants 9 months of age:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
European participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained 15 micrograms (µg) of O-antigen (OAg) each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 High Dose
European participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 169. High dose of altSonflex1-2-3 contained 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 High Dose
European participants 18-50 years of age were randomized to receive 1 dose of Placebo on Day 1 and on Day 85 or 169. All participants in Step 1 that received placebo were pooled, as pre-specified in Statistical Analysis Plan.
Drug: altSonflex Placebo
African participants 18-50 years of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained of 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 High Dose
African participants 18-50 years of age were randomized to receive 1 dose of MENVEO as comparator on Day 1 and 1 dose of BOOSTRIX as comparator Day 85.
Biological: Menveo · Combination Product: Boostrix
African participants 24-59 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1 and Day 85. Medium dose of altSonflex1-2-3 contained 7.5 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 Medium Dose
African participants 24-59 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1 and Day 85. High dose of altSonflex1-2-3 contained 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 High Dose
African participants 24-59 months of age were randomized to receive 1 dose of MENVEO as comparator on Day 1 and 1 dose of TYPHIM VI as comparator on Day 85.
Biological: Menveo · Combination Product: Typhim-Vi
African participants 9 months of age were randomized to receive a low dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. The measles-rubella vaccine (MR-VAC) was administered on Day 29 and Day 281. Low dose of altSonflex1-2-3 contained 3.75 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 Low Dose · Biological: MR-Vac
African participants 9 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was administered on Day 29 and Day 281. Medium dose of altSonflex1-2-3 contained 7.5 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 Medium Dose · Biological: MR-Vac
African participants 9 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was administered on Day 29 and Day 281. High dose of altSonflex1-2-3 contained 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 High Dose · Biological: MR-Vac
African participants 9 months of age were randomized to receive a dose of MENVEO as comparator on Day 1 and Day 85 and INFRANRIX HEXA as comparator on Day 253. MR-VAC was administered on Day 29 and Day 281.
Biological: Menveo · Combination Product: INFANRIX HEXA · Biological: MR-Vac
African participants 9 months of age were randomized to receive a low dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. Low dose of altSonflex1-2-3 contained 3.75 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 Low Dose · Biological: MR-Vac
African participants 9 months of age were randomized to receive a medium dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. Medium dose of altSonflex1-2-3 contained 7.5 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 Medium Dose · Biological: MR-Vac
African participants 9 months of age were randomized to receive a high dose of altSonflex1-2-3 on Day 1, Day 85 and Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses. High dose of altSonflex1-2-3 contained 15 µg OAg of each Shigella serotype (S. sonnei, S. flexneri 1b, S. flexneri 2a, S. flexneri 3a).
Biological: AltSonflex1-2-3 High Dose · Biological: MR-Vac
African participants 9 months of age were randomized to receive a dose of MENVEO as comparator on Day 1 and Day 85 and INFRANRIX HEXA as comparator on Day 253. MR-VAC was co-administered on Day 1 and Day 253. This cohort was created to identify the preferred dose among low, medium and high doses.
Biological: Menveo · Combination Product: INFANRIX HEXA · Biological: MR-Vac
2 doses in adults 18-50 years of age and children 24-59 months of age, 3 doses in infants 9 months of age
2 doses in children 24-59 months of age, 3 doses in infants 9 months of age
3 doses in infants 9 months of age
1 dose in adults 18-50 years of age (stage 2) and children 24-59 months of age and 2 doses in infants 9 months of age
1 dose in adults 18-50 years of age (stage 2)
1 dose in infants 9 months of age
1 dose in children 24-59 months of age
2 doses in children 24-59 months of age
2 doses in adults 18-50 years of age (stage 1)
Stage 2: Geometric Mean Concentrations (GMCs) of Anti-serotype Specific Shigella Lipopolysaccharide (LPS)/O-Antigen (OAg) Serum Immunoglobulin G (IgG) in Participants 9 Months of Age in Africa
Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by enzyme-linked immunosorbent assay (ELISA) and expressed in ELISA units per milliliter (EU/mL) of serum. Four serotypes were tested. Due to the fact, that the Per protocol set (PPS) for Stage 2 Infants - dose finding cohort had less than the 72 participants per group defined in the protocol as a minimum number of participants to ensure power of the analysis, the Stage 2 Infants Safety cohort and Dose-finding cohort were pooled for the statistical analysis as per the Statistical Analysis Plan. As per protocol, statistical analysis was performed only for the S. sonnei serotype, comparing Stage 2 Infants: Pooled groups (medium vs low dose); and Stage 2 Infants Dose-finding groups (high vs low dose). The objective of this outcome measure is to identify the preferred dose of each component of the altSonflex1-2-3 vaccine for infants 9 months of age in Africa, therefore control groups were not analyzed.
Time frame: At Day 281 (28 days after the third study intervention)
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Solicited Administration Site Events
The solicited administration site events assessed were erythema, pain, and swelling.
Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])
Stage 1: Number of Adults 18 to 50 Years of Age in Europe With Solicited Systemic Events
The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Unsolicited Adverse Events (AEs)
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
Time frame: Within 28 days after each study intervention (administered at at Day 1, Day 85 and Day 169 [depending on the vaccination schedule])
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
Time frame: From Day 1 to Day 113 and/or Day 197
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 8
Stage 1: Number of Participants 18 to 50 Years of Age in Europe With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85/Day 169 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 92 (Stage 1 Adults: altSonflex1-2-3 High Dose Group 1), at Day 176 (Stage 1 Adults: altSonflex1-2-3 High Dose Group 2) and at Day 92/Day 176 (Stage 1 Adults: Placebo Group)
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Administration Site Events
The solicited administration site events assessed were pain, erythema, and swelling.
Time frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Solicited Systemic Events
The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
Time frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Unsolicited Adverse Events (AEs)
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
Time frame: Within 28 days after each study intervention (administered at Day 1 and Day 85)
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
Time frame: From Day 1 to Day 113
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 8
Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 92
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Administration Site Events
The solicited administration site events assessed were erythema, pain, and swelling.
Time frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Solicited Systemic Events
The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
Time frame: Within 7 days after each study intervention (administered at Day 1 and Day 85)
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Unsolicited Adverse Events (AEs)
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
Time frame: Within 28 days after each study intervention (administered at Day 1 and Day 85)
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
Time frame: From Day 1 to Day 113
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 8
Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 92
Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Safety Cohort
The solicited administration site events assessed were erythema, pain, and swelling.
Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Administration Site Events - Infants Dose-finding Cohort
The solicited administration site events assessed were erythema, pain, and swelling.
Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Safety Cohort
The solicited systemic event is fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Stage 2: Number of Participants 9 Months of Age in Africa With Solicited Systemic Events - Infants Dose-finding Cohort
The solicited systemic event is fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
Time frame: Within 7 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Stage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Safety Cohort
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
Time frame: Within 28 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Stage 2: Number of Participants 9 Months of Age in Africa With Unsolicited Adverse Events (AEs) - Infants Dose-finding Cohort
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
Time frame: Within 28 days after each study intervention (administered at Day 1, Day 85 and Day 253)
Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Safety Cohort
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
Time frame: From Day 1 to Day 281
Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Dose-finding Cohort
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
Time frame: From Day 1 to Day 281
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Safety Cohort
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 8
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After First Study Intervention - Infants Dose-finding Cohort
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 8
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Safety Cohort
Panel tests include measures of ALT, AST, creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 92
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Second Study Intervention - Infants Dose-finding Cohort
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 92
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Safety Cohort
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 260
Stage 2: Number of Participants 9 Months of Age in Africa With Deviations From Normal Values of Haematological, Renal, and Hepatic Panel Test Results After Third Study Intervention - Infants Dose-finding Cohort
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
Time frame: At Day 260
Stage 1: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 18 to 50 Years of Age in Europe
Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by ELISA and expressed in EU/mL of serum. S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.
Time frame: At Day 1 and Day 85/Day 169(before each study intervention); at Day 15 (14 days after the first study intervention); at Day 29 and Day 113/Day 197 (28 days after each study intervention)
Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 18 to 50 Years of Age in Africa
Time frame: At Day 1 and Day 85 (before each study intervention administration) and Day 29 and Day 113 (28 days after each study intervention administration)
Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 24 to 59 Months of Age in Africa
Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 9 Months of Age in Africa - Infants Safety Cohort
Time frame: At Day 1, Day 85 and Day 253 (before each study intervention administration) and Day 29, Day 113 and Day 281 (28 days after each study intervention administration)
Stage 2: Anti-serotype Specific Shigella LPS/OAg Serum IgG GMCs in Participants 9 Months of Age in Africa - Dose-finding Cohort
Time frame: At Day 1, Day 85 and Day 253 (before each study intervention administration) and Day 29, Day 113 and Day 281 (28 days after each study intervention administration)
Stage 1: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg
Time frame: At Day 1 and Day 85/Day 169 (before each study intervention); at Day 15 (14 days after the first study intervention); at Day 29 and Day 113/Day 197 (28 days after each study intervention)
Stage 2: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg
Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Stage 2: Number of Participants 24 to 59 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/OAg
Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/Oag - Safety Cohort
Time frame: At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)
Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:800 Titer Against S. Sonnei LPS/Oag - Dose-finding Cohort
Time frame: At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)
Stage 1: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg
Time frame: At Day 1 and Day 85/Day 169 (before each study intervention); at Day 15 (14 days after the first study intervention); at Day 29 and Day 113/Day 197 (28 days after each study intervention)
Stage 2: Number of Participants 18 to 50 Years of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg
Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Stage 2: Number of Participants 24 to 59 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg
Time frame: At Day 1 and Day 85 (before each study intervention) and Day 29 and Day 113 (28 days after each study intervention)
Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg - Safety Cohort
Time frame: At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)
Stage 2: Number of Participants 9 Months of Age Achieving a GVGH ELISA Level Equivalent to ≥1:1600 Titer Against S. Sonnei LPS/OAg - Dose-finding Cohort
Time frame: At Day 1, Day 85 and Day 253 (before each study intervention) and Day 29, Day 113 and Day 281 (28 days after each study intervention)
Stage 1: Number of Participants 18 to 50 Years of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA
Time frame: At Day 15 (14 days after the first study intervention) and at Day 29 and Day 113/Day 197 (28 days after each study intervention) compared to baseline (Day 1 and Day 85/Day 169)
Stage 2: Number of Participants 18 to 50 Years of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA
Time frame: At Day 29 and Day 113 (28 days after each study intervention) compared to baseline (Day 1 and Day 85)
Stage 2: Number of Participants 24 to 59 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA
Time frame: At Day 29 and Day 113 (28 days after each study intervention) compared to baseline (Day 1 and Day 85)
Stage 2: Number of Participants 9 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA - Safety Cohort
Time frame: At Day 29, Day 113 and Day 281 (28 days after each study intervention) compared to baseline (Day 1, Day 85 and Day 253)
Stage 2: Number of Participants 9 Months of Age Showing at Least a 4-fold Increase in Anti-serotype Specific Shigella LPS/OAg Serum IgG Concentrations, as Measured by GVGH ELISA - Dose-finding Cohort
Time frame: At Day 29, Day 113 and Day 281 (28 days after each study intervention) compared to baseline (Day 1, Day 85 and Day 253)
Stage 2: Anti-measles IgG Concentrations in Participants 9 Months of Age in the Dose-finding Cohort
Time frame: At Day 1 (before first measles and rubella vaccine (MR-VAC)) and at Day 281 (28 days after the second MR-VAC administration)
Stage 2: Anti-rubella IgG Concentrations in Participants 9 Months of Age in the Dose-finding Groups
Time frame: At Day 1 (before first measles and rubella vaccine (MR-VAC)) and at Day 281 (28 days after the second MR-VAC administration)
Stage 2: Number of Participants 9 Months of Age in the Dose-finding Groups Achieving Anti-measles IgG Concentrations of ≥150 Milli International Units Per Milliliter (mIU/mL) and ≥200 mIU/mL
Time frame: Day 281 (28 days after the second MR-VAC administration)
Stage 2: Number of Participants 9 Months of Age in the Dose-finding Groups Achieving Anti-rubella IgG Concentrations of ≥4 mIU/mL and ≥10 mIU/mL
Time frame: Day 281 (28 days after the second MR-VAC administration)
Out of 551 participants enrolled, 550 started the study and were included in the Exposed set.
| Milestone | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 34 | 34 | 34 | 10 | 10 | 10 | 10 | 20 | 10 | 10 | 10 | 30 | 82 | 81 | 83 | 82 |
| Completed | 29 | 34 | 28 | 10 | 10 | 10 | 10 | 20 | 9 | 8 | 10 | 27 | 69 | 71 | 73 | 71 |
| Not completed | 5 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 3 | 13 | 10 | 10 | 11 |
| Withdrew: Adverse events (including death) | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 2 | 5 |
| Withdrew: Consent withdrawal, not due to a (serious) adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 9 | 4 | 5 | 5 |
| Withdrew: Migrated / moved from the study area | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 2 | 2 | 0 |
| Withdrew: Other | 2 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by enzyme-linked immunosorbent assay (ELISA) and expressed in ELISA units per milliliter (EU/mL) of serum. Four serotypes were tested. Due to the fact, that the Per protocol set (PPS) for Stage 2 Infants - dose finding cohort had less than the 72 participants per group defined in the protocol as a minimum number of participants to ensure power of the analysis, the Stage 2 Infants Safety cohort and Dose-finding cohort were pooled for the statistical analysis as per the Statistical Analysis Plan. As per protocol, statistical analysis was performed only for the S. sonnei serotype, comparing Stage 2 Infants: Pooled groups (medium vs low dose); and Stage 2 Infants Dose-finding groups (high vs low dose). The objective of this outcome measure is to identify the preferred dose of each component of the altSonflex1-2-3 vaccine for infants 9 months of age in Africa, therefore control groups were not analyzed.
| ELISA units per milliliter (EU/mL) | Stage 2 Infants: altSonflex1-2-3 Low Dose Pooled | Stage 2 Infants: altSonflex1-2-3 Medium Dose Pooled | Stage 2 Infants: altSonflex1-2-3 High Dose Pooled | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose |
|---|---|---|---|---|---|---|
| S. sonnei Ab IgG | 379.3 (81.4 to 1766.5) | 463.5 (95.0 to 2261.3) | 457.6 (94.7 to 2211.3) | 437.3 (335.3 to 570.4) | 577.5 (449.7 to 741.7) | 584.3 (451.9 to 755.5) |
| S. flexneri 1b Ab IgG | 51.1 (39.3 to 66.4) | 32.1 (25.6 to 40.4) | 35.6 (28.3 to 44.8) | 56.6 (44.0 to 72.9) | 33.1 (25.1 to 43.7) | 35.1 (27.0 to 45.7) |
| S. flexneri 2a Ab IgG | 177.8 (57.4 to 550.6) | 135.3 (34.0 to 537.9) | 173.8 (62.4 to 484.0) | 186.3 (141.2 to 245.8) | 145.9 (115.2 to 184.9) | 180.8 (136.9 to 238.7) |
| S. flexneri 3a Ab IgG | 32.6 (6.1 to 173.2) | 24.4 (4.8 to 125.4) | 27.5 (5.0 to 152.2) | 39.7 (28.9 to 54.6) | 30.4 (22.3 to 41.5) | 36.6 (25.8 to 51.9) |
The solicited administration site events assessed were erythema, pain, and swelling.
| Participants | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| Erythema, Vaccination at Day 1 | 4 | 6 | 1 |
| Erythema, Vaccination at Day 85 | 2 | — | — |
| Erythema, Vaccination at 169 | — | 4 | — |
| Erythema, Vaccination at Day 85/169 | — | — | 0 |
| Pain, Vaccination at Day 1 | 32 | 33 | 16 |
| Pain, Vaccination at Day 85 | 22 | — | — |
| Pain, Vaccination at Day 169 | — | 31 | — |
| Pain, Vaccination at Day 85/169 | — | — | 8 |
| Swelling, Vaccination at Day 1 | 2 | 7 | 0 |
| Swelling, Vaccination at Day 85 | 5 | — | — |
| Swelling, Vaccination at 169 | — | 5 | — |
| Swelling, Vaccination at Day 85/169 | — | — | 0 |
The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
| Participants | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| Within 7 days after vaccination at Day 1 | 0 | 1 | 0 |
| Within 7 days after vaccination at Day 85 | 2 | — | — |
| Within 7 days after vaccination at Day 169 | — | 1 | — |
| Within 7 days after vaccination at Day 85/169 | — | — | 1 |
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
| Participants | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| Within 28 days after vaccination at Day 1 | 25 | 21 | 25 |
| Within 28 days after vaccination at Day 85 | 14 | — | — |
| Within 28 days after vaccination at Day 169 | — | 14 | — |
| Within 28 days after vaccination at Day 85/169 | — | — | 12 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
| Participants | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| From Day 1 to Day 113 | 0 | — | — |
| From Day 1 to Day 197 | — | 1 | — |
| From Day 1 to Day 113/197 | — | — | 0 |
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| ALT, Within, Within | 32 | 33 | 30 |
| ALT, Within, Above | 1 | 0 | 1 |
| ALT, Above, Within | 1 | 0 | 1 |
| ALT, Above, Above | 0 | 1 | 2 |
| AST, Within, Within | 31 | 33 | 31 |
| AST, Within, Above | 0 | 0 | 3 |
| AST, Above, Within | 3 | 0 | 0 |
| AST, Above, Above | 0 | 1 | 0 |
| Creatinine, Within, Within | 33 | 34 | 34 |
| Creatinine, Above, Above | 1 | 0 | 0 |
| Basophils, Below, Below | 0 | 0 | 1 |
| Basophils, Below, Within | 3 | 0 | 1 |
| Basophils, Within, Below | 0 | 0 | 1 |
| Basophils, Within, Within | 31 | 33 | 31 |
| Basophils, Above, Within | 0 | 1 | 0 |
| Eosinophils, Below, Within | 1 | 1 | 1 |
| Eosinophils, Within, Below | 0 | 2 | 0 |
| Eosinophils, Within, Within | 32 | 30 | 31 |
| Eosinophils, Within, Above | 0 | 0 | 1 |
| Eosinophils, Above, Within | 1 | 0 | 0 |
| Eosinophils, Above, Above | 0 | 1 | 1 |
| Erythrocytes, Below, Below | 1 | 0 | 0 |
| Erythrocytes, Below, Within | 1 | 0 | 0 |
| Erythrocytes, Within, Below | 0 | 1 | 0 |
| Erythrocytes, Within, Within | 32 | 32 | 33 |
| Erythrocytes, Above, Within | 0 | 1 | 1 |
| Haematocrit, Below, Below | 0 | 1 | 0 |
| Haematocrit, Below, Within | 1 | 0 | 1 |
| Haematocrit, Within, Within | 32 | 32 | 33 |
| Haematocrit, Above, Within | 1 | 0 | 0 |
| Haematocrit, Above, Above | 0 | 1 | 0 |
| Haemoglobin, Below, Below | 1 | 1 | 0 |
| Haemoglobin, Below, Within | 2 | 1 | 0 |
| Haemoglobin, Within, Below | 0 | 1 | 0 |
| Haemoglobin, Within, Within | 30 | 28 | 33 |
| Haemoglobin, Within, Above | 0 | 1 | 0 |
| Haemoglobin, Above, Within | 1 | 1 | 1 |
| Haemoglobin, Above, Above | 0 | 1 | 0 |
| Lymphocytes, Below, Below | 2 | 2 | 0 |
| Lymphocytes, Below, Within | 1 | 0 | 1 |
| Lymphocytes, Within, Within | 31 | 32 | 31 |
| Lymphocytes, Within, Above | 0 | 0 | 2 |
| Monocytes, Below, Within | 0 | 1 | 1 |
| Monocytes, Within, Below | 1 | 0 | 0 |
| Monocytes, Within, Within | 33 | 33 | 31 |
| Monocytes, Above, Within | 0 | 0 | 1 |
| Monocytes, Above, Above | 0 | 0 | 1 |
| Neutrophils, Below, Within | 1 | 0 | 1 |
| Neutrophils, Below, Above | 1 | 0 | 0 |
| Neutrophils, Within, Below | 0 | 2 | 1 |
| Neutrophils, Within, Within | 28 | 28 | 32 |
| Neutrophils, Within, Above | 1 | 3 | 0 |
| Neutrophils, Above, Within | 3 | 1 | 0 |
| Platelets, Below, Within | 0 | 1 | 2 |
| Platelets, Within, Within | 29 | 28 | 29 |
| Platelets, Within, Above | 0 | 3 | 1 |
| Platelets, Above, Within | 1 | 0 | 1 |
| Platelets, Above, Above | 4 | 2 | 1 |
| WBC, Below, Within | 2 | 1 | 2 |
| WBC, Within, Below | 1 | 4 | 0 |
| WBC, Within, Within | 30 | 29 | 32 |
| WBC, Within, Above | 1 | 0 | 0 |
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85/Day 169 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| ALT, Within, Within | 26 | 32 | 26 |
| ALT, Within, Above | 1 | 0 | 0 |
| ALT, Above, Within | 1 | 1 | 1 |
| ALT, Above, Above | 1 | 1 | 1 |
| AST, Within, Within | 27 | 32 | 27 |
| AST, Within, Above | 1 | 0 | 0 |
| AST, Above, Within | 1 | 1 | 1 |
| AST, Above, Above | 0 | 1 | 0 |
| Creatinine, Within, Within | 28 | 34 | 27 |
| Creatinine, Within, Above | 0 | 0 | 1 |
| Creatinine, Above, Above | 1 | 0 | 0 |
| Basophils, Below, Below | 0 | 0 | 1 |
| Basophils, Below, Within | 1 | 1 | 1 |
| Basophils, Within, Below | 2 | 0 | 0 |
| Basophils, Within, Within | 26 | 33 | 25 |
| Basophils, Within, Above | 0 | 0 | 1 |
| Eosinophils, Below, Below | 0 | 2 | 0 |
| Eosinophils, Within, Below | 1 | 0 | 1 |
| Eosinophils, Within, Within | 25 | 30 | 24 |
| Eosinophils, Within, Above | 1 | 1 | 1 |
| Eosinophils, Above, Within | 0 | 0 | 1 |
| Eosinophils, Above, Above | 2 | 1 | 1 |
| Erythrocytes, Within, Below | 0 | 0 | 1 |
| Erythrocytes, Within, Within | 29 | 32 | 27 |
| Erythrocytes, Above, Within | 0 | 1 | 0 |
| Erythrocytes, Above, Above | 0 | 1 | 0 |
| Haematocrit, Below, Below | 0 | 1 | 0 |
| Haematocrit, Within, Below | 0 | 1 | 0 |
| Haematocrit, Within, Within | 29 | 31 | 28 |
| Haematocrit, Above, Within | 0 | 1 | 0 |
| Haemoglobin, Below, Below | 0 | 1 | 0 |
| Haemoglobin, Below, Within | 1 | 0 | 0 |
| Haemoglobin, Within, Below | 0 | 1 | 0 |
| Haemoglobin, Within, Within | 27 | 30 | 28 |
| Haemoglobin, Within, Above | 1 | 0 | 0 |
| Haemoglobin, Above, Within | 0 | 2 | 0 |
| Lymphocytes, Below, Below | 1 | 1 | 1 |
| Lymphocytes, Below, Within | 2 | 2 | 0 |
| Lymphocytes, Within, Below | 0 | 3 | 0 |
| Lymphocytes, Within, Within | 25 | 28 | 27 |
| Lymphocytes, Within, Above | 1 | 0 | 0 |
| Monocytes, Below, Below | 0 | 0 | 1 |
| Monocytes, Below, Within | 1 | 1 | 1 |
| Monocytes, Within, Within | 28 | 30 | 23 |
| Monocytes, Within, Above | 0 | 2 | 0 |
| Monocytes, Above, Within | 0 | 1 | 3 |
| Neutrophils, Below, Below | 0 | 0 | 1 |
| Neutrophils, Below, Within | 2 | 3 | 0 |
| Neutrophils, Within, Below | 1 | 0 | 1 |
| Neutrophils, Within, Within | 26 | 26 | 22 |
| Neutrophils, Within, Above | 0 | 2 | 1 |
| Neutrophils, Above, Within | 0 | 2 | 2 |
| Neutrophils, Above, Above | 0 | 1 | 1 |
| Platelets, Below, Within | 1 | 0 | 1 |
| Platelets, Within, Below | 1 | 0 | 1 |
| Platelets, Within, Within | 23 | 29 | 23 |
| Platelets, Within, Above | 1 | 2 | 3 |
| Platelets, Above, Within | 3 | 0 | 0 |
| Platelets, Above, Above | 0 | 3 | 0 |
| WBC, Below, Below | 1 | 3 | 1 |
| WBC, Below, Within | 2 | 2 | 0 |
| WBC, Within, Below | 1 | 0 | 1 |
| WBC, Within, Within | 25 | 26 | 24 |
| WBC, Within, Above | 0 | 3 | 0 |
| WBC, Above, Within | 0 | 0 | 1 |
| WBC, Above, Above | 0 | 0 | 1 |
The solicited administration site events assessed were pain, erythema, and swelling.
| Participants | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| Pain, Vaccination at Day 1 | 5 | 2 |
| Pain, Vaccination at Day 85 | 4 | 3 |
| Erythema, Vaccination at Day 1 | 0 | 0 |
| Erythema, Vaccination at Day 85 | 0 | 0 |
| Swelling, Vaccination at Day 1 | 0 | 0 |
| Swelling, Vaccination at Day 85 | 0 | 0 |
The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
| Participants | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| Vaccination at Day 1 | 0 | 0 |
| Vaccination at Day 85 | 0 | 0 |
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
| Participants | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| Vaccination at Day 1 | 2 | 1 |
| Vaccination at Day 85 | 2 | 2 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
| Participants | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| Stage 2: Number of Participants 18 to 50 Years of Age in Africa With Serious Adverse Events (SAEs) | 0 | 0 |
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| ALT, Within, Below | 0 | 1 |
| ALT, Within, Within | 10 | 9 |
| AST, Within, Within | 10 | 10 |
| Creatinine, Below, Below | 6 | 6 |
| Creatinine, Below, Within | 1 | 0 |
| Creatinine, Within, Below | 0 | 1 |
| Creatinine, Within, Within | 3 | 3 |
| Basophils, Within, Within | 10 | 10 |
| Eosinophils, Within, Below | 0 | 1 |
| Eosinophils, Within, Within | 10 | 9 |
| Erythrocytes, Within, Within | 10 | 10 |
| Haematocrit, Within, Within | 10 | 10 |
| Haemoglobin, Within, Within | 10 | 10 |
| Lymphocytes, Below, Within | 0 | 2 |
| Lymphocytes, Within, Within | 9 | 8 |
| Lymphocytes, Above, Above | 1 | 0 |
| Monocytes, Within, Within | 9 | 7 |
| Monocytes, Within, Above | 0 | 1 |
| Monocytes, Above, Above | 1 | 2 |
| Neutrophils, Within, Within | 9 | 9 |
| Neutrophils, Within, Above | 1 | 1 |
| Platelets, Within, Within | 10 | 10 |
| WBC, Below, Within | 0 | 1 |
| WBC, Within, Within | 8 | 8 |
| WBC, Within, Above | 1 | 1 |
| WBC, Above, Above | 1 | 0 |
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| ALT, Within, Within | 9 | 10 |
| ALT, Within, Above | 1 | 0 |
| AST, Below, Within | 1 | 0 |
| AST, Within, Within | 8 | 10 |
| AST, Within, Above | 1 | 0 |
| Creatinine, Below, Below | 6 | 4 |
| Creatinine, Within, Below | 1 | 2 |
| Creatinine, Within, Within | 3 | 4 |
| Basophils, Within, Within | 10 | 10 |
| Eosinophils, Below, Within | 0 | 1 |
| Eosinophils, Within, Within | 10 | 9 |
| Erythrocytes, Within, Within | 10 | 10 |
| Haematocrit, Within, Within | 10 | 10 |
| Haemoglobin, Within, Within | 10 | 10 |
| Lymphocytes, Below, Within | 0 | 1 |
| Lymphocytes, Within, Within | 9 | 9 |
| Lymphocytes, Above, Above | 1 | 0 |
| Monocytes, Within, Within | 7 | 9 |
| Monocytes, Within, Above | 2 | 1 |
| Monocytes, Above, Within | 1 | 0 |
| Neutrophils, Within, Within | 8 | 10 |
| Neutrophils, Within, Above | 1 | 0 |
| Neutrophils, Above, Within | 1 | 0 |
| Platelets, Within, Within | 9 | 10 |
| Platelets, Within, Above | 1 | 0 |
| WBC, Within, Within | 8 | 10 |
| WBC, Within, Above | 1 | 0 |
| WBC, Above, Within | 1 | 0 |
The solicited administration site events assessed were erythema, pain, and swelling.
| Participants | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| Erythema, Vaccination at Day 1 | 1 | 1 | 0 |
| Erythema, Vaccination at Day 85 | 1 | 0 | 0 |
| Pain, Vaccination at Day 1 | 6 | 2 | 3 |
| Pain, Vaccination at Day 85 | 7 | 2 | 3 |
| Swelling, Vaccination at Day 1 | 1 | 1 | 0 |
| Swelling, Vaccination at Day 85 | 1 | 0 | 0 |
The solicited systemic event assessed was fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
| Participants | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| Vaccination at Day 1 | 1 | 1 | 0 |
| Vaccination at Day 85 | 1 | 2 | 3 |
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
| Participants | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| Vaccination at Day 1 | 4 | 3 | 8 |
| Vaccination at Day 85 | 2 | 0 | 3 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
| Participants | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| Stage 2: Number of Participants 24 to 59 Months of Age in Africa With Serious Adverse Events (SAEs) | 0 | 0 | 0 |
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| ALT, Within, Within | 8 | 9 | 16 |
| ALT, Within, Above | 0 | 1 | 1 |
| ALT, Above, Within | 0 | 0 | 2 |
| ALT, Above, Above | 2 | 0 | 1 |
| AST, Within, Within | 8 | 10 | 20 |
| AST, Above, Within | 2 | 0 | 0 |
| Creatinine, Below, Below | 8 | 9 | 17 |
| Creatinine, Below, Within | 1 | 0 | 0 |
| Creatinine, Within, Below | 1 | 1 | 1 |
| Creatinine, Within, Within | 0 | 0 | 1 |
| Creatinine, Above, Within | 0 | 0 | 1 |
| Basophils, Within, Below | 0 | 0 | 1 |
| Basophils, Within, Within | 9 | 10 | 16 |
| Basophils, Within, Above | 1 | 0 | 2 |
| Basophils, Above, Within | 0 | 0 | 1 |
| Eosinophils, Below, Within | 1 | 0 | 0 |
| Eosinophils, Within, Below | 0 | 0 | 1 |
| Eosinophils, Within, Within | 5 | 6 | 12 |
| Eosinophils, Within, Above | 0 | 0 | 1 |
| Eosinophils, Above, Within | 0 | 1 | 1 |
| Eosinophils, Above, Above | 4 | 3 | 5 |
| Erythrocytes, Within, Within | 8 | 9 | 12 |
| Erythrocytes, Within, Above | 1 | 0 | 0 |
| Erythrocytes, Above, Within | 0 | 1 | 5 |
| Erythrocytes, Above, Above | 1 | 0 | 3 |
| Haematocrit, Below, Below | 0 | 1 | 0 |
| Haematocrit, Within, Within | 8 | 7 | 14 |
| Haematocrit, Within, Above | 0 | 0 | 1 |
| Haematocrit, Above, Within | 2 | 2 | 5 |
| Haemoglobin, Below, Below | 0 | 1 | 0 |
| Haemoglobin, Below, Within | 1 | 0 | 0 |
| Haemoglobin, Within, Below | 0 | 0 | 1 |
| Haemoglobin, Within, Within | 7 | 7 | 18 |
| Haemoglobin, Above, Within | 1 | 2 | 0 |
| Haemoglobin, Above, Above | 1 | 0 | 1 |
| Lymphocytes, Within, Within | 7 | 7 | 8 |
| Lymphocytes, Within, Above | 1 | 0 | 2 |
| Lymphocytes, Above, Within | 2 | 1 | 7 |
| Lymphocytes, Above, Above | 0 | 2 | 3 |
| Monocytes, Within, Within | 9 | 8 | 13 |
| Monocytes, Within, Above | 1 | 2 | 3 |
| Monocytes, Above, Within | 0 | 0 | 1 |
| Monocytes, Above, Above | 0 | 0 | 3 |
| Neutrophils, Below, Below | 0 | 0 | 1 |
| Neutrophils, Below, Within | 2 | 0 | 2 |
| Neutrophils, Within, Below | 2 | 0 | 1 |
| Neutrophils, Within, Within | 6 | 10 | 16 |
| Platelets, Within, Within | 1 | 3 | 4 |
| Platelets, Within, Above | 5 | 4 | 2 |
| Platelets, Above, Within | 0 | 0 | 4 |
| Platelets, Above, Above | 4 | 3 | 10 |
| WBC, Below, Within | 1 | 0 | 0 |
| WBC, Within, Within | 9 | 10 | 19 |
| WBC, Above, Above | 0 | 0 | 1 |
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 85 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| ALT, Within, Within | 9 | 5 | 15 |
| ALT, Within, Above | 0 | 0 | 2 |
| ALT, Above, Within | 0 | 2 | 1 |
| ALT, Above, Above | 1 | 3 | 2 |
| AST, Within, Within | 10 | 10 | 19 |
| AST, Within, Above | 0 | 0 | 1 |
| Creatinine, Below, Below | 10 | 8 | 18 |
| Creatinine, Within, Below | 0 | 2 | 2 |
| Basophils, Within, Within | 9 | 9 | 20 |
| Basophils, Above, Within | 1 | 0 | 0 |
| Basophils, Above, Above | 0 | 1 | 0 |
| Eosinophils, Within, Below | 1 | 0 | 0 |
| Eosinophils, Within, Within | 6 | 8 | 16 |
| Eosinophils, Within, Above | 1 | 0 | 1 |
| Eosinophils, Above, Above | 2 | 2 | 3 |
| Erythrocytes, Below, Within | 1 | 0 | 0 |
| Erythrocytes, Within, Within | 7 | 8 | 17 |
| Erythrocytes, Within, Above | 1 | 0 | 1 |
| Erythrocytes, Above, Within | 0 | 1 | 0 |
| Erythrocytes, Above, Above | 1 | 1 | 2 |
| Haematocrit, Below, Below | 1 | 0 | 0 |
| Haematocrit, Below, Within | 0 | 0 | 1 |
| Haematocrit, Within, Within | 9 | 10 | 19 |
| Haemoglobin, Below, Below | 1 | 0 | 1 |
| Haemoglobin, Within, Below | 0 | 0 | 1 |
| Haemoglobin, Within, Within | 9 | 8 | 18 |
| Haemoglobin, Above, Within | 0 | 2 | 0 |
| Lymphocytes, Within, Within | 7 | 6 | 14 |
| Lymphocytes, Within, Above | 0 | 0 | 2 |
| Lymphocytes, Above, Within | 3 | 2 | 3 |
| Lymphocytes, Above, Above | 0 | 2 | 1 |
| Monocytes, Below, Within | 0 | 1 | 0 |
| Monocytes, Within, Within | 9 | 7 | 13 |
| Monocytes, Within, Above | 1 | 0 | 2 |
| Monocytes, Above, Within | 0 | 0 | 4 |
| Monocytes, Above, Above | 0 | 2 | 1 |
| Neutrophils, Below, Below | 2 | 0 | 0 |
| Neutrophils, Below, Within | 1 | 0 | 1 |
| Neutrophils, Within, Below | 0 | 0 | 1 |
| Neutrophils, Within, Within | 5 | 10 | 18 |
| Neutrophils, Within, Above | 2 | 0 | 0 |
| Platelets, Within, Within | 3 | 3 | 7 |
| Platelets, Within, Above | 1 | 1 | 5 |
| Platelets, Above, Within | 2 | 1 | 2 |
| Platelets, Above, Above | 4 | 5 | 6 |
| WBC, Below, Within | 2 | 0 | 0 |
| WBC, Within, Within | 7 | 10 | 19 |
| WBC, Above, Above | 1 | 0 | 1 |
The solicited administration site events assessed were erythema, pain, and swelling.
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| Erythema, Vaccination at Day 1 | 0 | 0 | 3 | 1 |
| Erythema, Vaccination at Day 85 | 0 | 1 | 2 | 0 |
| Erythema, Vaccination at Day 253 | 0 | 0 | 4 | 0 |
| Pain, Vaccination at Day 1 | 2 | 3 | 7 | 3 |
| Pain, Vaccination at Day 85 | 2 | 3 | 6 | 3 |
| Pain, Vaccination at Day 253 | 2 | 4 | 7 | 6 |
| Swelling, Vaccination at Day 1 | 0 | 1 | 4 | 2 |
| Swelling, Vaccination at Day 85 | 0 | 1 | 2 | 1 |
| Swelling, Vaccination at Day 253 | 1 | 0 | 5 | 3 |
The solicited administration site events assessed were erythema, pain, and swelling.
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| Erythema, Vaccination at Day 1 | 16 | 9 | 21 | 9 |
| Erythema, Vaccination at Day 85 | 11 | 12 | 11 | 4 |
| Erythema, Vaccination at Day 253 | 6 | 7 | 11 | 8 |
| Pain, Vaccination at Day 1 | 40 | 42 | 43 | 14 |
| Pain, Vaccination at Day 85 | 34 | 36 | 43 | 20 |
| Pain, Vaccination at Day 253 | 27 | 39 | 41 | 26 |
| Swelling, Vaccination at Day 1 | 21 | 21 | 21 | 9 |
| Swelling, Vaccination at Day 85 | 19 | 20 | 22 | 2 |
| Swelling, Vaccination at Day 253 | 15 | 12 | 17 | 14 |
The solicited systemic event is fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| Vaccination at Day 1 | 3 | 1 | 4 | 5 |
| Vaccination at Day 85 | 2 | 1 | 1 | 2 |
| Vaccination at Day 253 | 1 | 2 | 2 | 4 |
The solicited systemic event is fever. Fever is defined as temperature equal to or above (=\>) 38.0°C.
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| Vaccination at Day 1 | 27 | 18 | 23 | 7 |
| Vaccination at Day 85 | 17 | 13 | 10 | 17 |
| Vaccination at Day 253 | 21 | 16 | 22 | 9 |
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| Vaccination at Day 1 | 2 | 3 | 4 | 17 |
| Vaccination at Day 85 | 1 | 4 | 6 | 10 |
| Vaccination at Day 253 | 4 | 2 | 4 | 4 |
An unsolicited AE is defined as an AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms is reported as an unsolicited adverse event.
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| Vaccination at Day 1 | 35 | 37 | 34 | 41 |
| Vaccination at Day 85 | 23 | 25 | 31 | 28 |
| Vaccination at Day 253 | 21 | 29 | 31 | 26 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Safety Cohort | 0 | 0 | 0 | 1 |
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| Stage 2: Number of Participants 9 Months of Age in Africa With Serious Adverse Events (SAEs) - Infants Dose-finding Cohort | 2 | 1 | 4 | 1 |
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| ALT, Below, Within | 0 | 0 | 1 | 0 |
| ALT, Within, Within | 10 | 9 | 9 | 29 |
| ALT, Within, Above | 0 | 0 | 0 | 1 |
| AST, Within, Within | 10 | 9 | 10 | 30 |
| Creatinine, Below, Below | 10 | 9 | 10 | 30 |
| Basophils, Within, Within | 8 | 0 | 10 | 18 |
| Basophils, Within, Above | 1 | 0 | 0 | 2 |
| Basophils, Above, Within | 1 | 1 | 0 | 1 |
| Basophils, Above, Above | 0 | 8 | 0 | 9 |
| Eosinophils, Within, Within | 10 | 8 | 10 | 28 |
| Eosinophils, Above, Above | 0 | 1 | 0 | 2 |
| Erythrocytes, Within, Within | 8 | 9 | 9 | 24 |
| Erythrocytes, Within, Above | 0 | 0 | 1 | 1 |
| Erythrocytes, Above, Within | 2 | 0 | 0 | 1 |
| Erythrocytes, Above, Above | 0 | 0 | 0 | 4 |
| Haematocrit, Below, Below | 1 | 0 | 0 | 1 |
| Haematocrit, Below, Within | 1 | 0 | 1 | 1 |
| Haematocrit, Within, Below | 1 | 1 | 0 | 0 |
| Haematocrit, Within, Within | 7 | 8 | 8 | 25 |
| Haematocrit, Within, Above | 0 | 0 | 1 | 0 |
| Haematocrit, Above, Within | 0 | 0 | 0 | 1 |
| Haematocrit, Above, Above | 0 | 0 | 0 | 2 |
| Haemoglobin, Below, Below | 2 | 0 | 0 | 1 |
| Haemoglobin, Below, Within | 1 | 0 | 1 | 1 |
| Haemoglobin, Within, Below | 1 | 3 | 1 | 4 |
| Haemoglobin, Within, Within | 6 | 6 | 6 | 23 |
| Haemoglobin, Within, Above | 0 | 0 | 1 | 1 |
| Haemoglobin, Above, Within | 0 | 0 | 1 | 0 |
| Lymphocytes, Within, Within | 8 | 5 | 9 | 15 |
| Lymphocytes, Within, Above | 1 | 1 | 1 | 5 |
| Lymphocytes, Above, Within | 1 | 1 | 0 | 3 |
| Lymphocytes, Above, Above | 0 | 2 | 0 | 7 |
| Monocytes, Below, Below | 0 | 1 | 0 | 0 |
| Monocytes, Below, Within | 0 | 0 | 1 | 1 |
| Monocytes, Within, Within | 7 | 7 | 6 | 23 |
| Monocytes, Within, Above | 0 | 0 | 1 | 3 |
| Monocytes, Above, Within | 0 | 1 | 2 | 2 |
| Monocytes, Above, Above | 3 | 0 | 0 | 1 |
| Neutrophils, Below, Below | 0 | 0 | 0 | 1 |
| Neutrophils, Below, Within | 2 | 0 | 2 | 2 |
| Neutrophils, Within, Below | 1 | 0 | 0 | 3 |
| Neutrophils, Within, Within | 6 | 9 | 8 | 24 |
| Neutrophils, Above, Within | 1 | 0 | 0 | 0 |
| Platelets, Within, Below | 0 | 0 | 0 | 1 |
| Platelets, Within, Within | 1 | 1 | 2 | 2 |
| Platelets, Within, Above | 2 | 0 | 4 | 8 |
| Platelets, Above, Within | 3 | 0 | 0 | 3 |
| Platelets, Above, Above | 4 | 8 | 4 | 16 |
| WBC, Below, Within | 0 | 0 | 1 | 1 |
| WBC, Within, Below | 0 | 0 | 0 | 1 |
| WBC, Within, Within | 8 | 7 | 9 | 22 |
| WBC, Within, Above | 1 | 0 | 0 | 4 |
| WBC, Above, Within | 0 | 1 | 0 | 0 |
| WBC, Above, Above | 1 | 1 | 0 | 2 |
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| ALT, Within, Within | 77 | 75 | 79 | 80 |
| ALT, Within, Above | 1 | 1 | 2 | 1 |
| ALT, Above, Within | 1 | 0 | 1 | 0 |
| AST, Within, Within | 76 | 76 | 78 | 81 |
| AST, Within, Above | 3 | 0 | 2 | 0 |
| AST, Above, Within | 0 | 0 | 2 | 0 |
| Creatinine, Below, Below | 79 | 76 | 81 | 81 |
| Creatinine, Within, Below | 0 | 0 | 1 | 0 |
| Potassium, Below, Within | 0 | 0 | 0 | 1 |
| Potassium, Within, Below | 0 | 0 | 1 | 0 |
| Potassium, Within, Within | 79 | 76 | 81 | 78 |
| Potassium, Within, Above | 0 | 0 | 0 | 1 |
| Potassium, Above, Within | 0 | 0 | 0 | 1 |
| Sodium, Within, Within | 40 | 35 | 39 | 37 |
| Sodium, Within, Above | 14 | 20 | 19 | 19 |
| Sodium, Above, Within | 8 | 11 | 14 | 14 |
| Sodium, Above, Above | 17 | 10 | 10 | 11 |
| Urea, Below, Below | 31 | 29 | 36 | 25 |
| Urea, Below, Within | 13 | 13 | 16 | 14 |
| Urea, Within, Below | 10 | 14 | 11 | 15 |
| Urea, Within, Within | 25 | 20 | 19 | 27 |
| Basophils, Within, Within | 69 | 70 | 73 | 68 |
| Basophils, Within, Above | 2 | 2 | 2 | 5 |
| Basophils, Above, Within | 5 | 4 | 7 | 6 |
| Basophils, Above, Above | 3 | 0 | 0 | 2 |
| Eosinophils, Below, Within | 0 | 2 | 3 | 1 |
| Eosinophils, Within, Below | 4 | 3 | 1 | 3 |
| Eosinophils, Within, Within | 70 | 65 | 73 | 66 |
| Eosinophils, Within, Above | 2 | 1 | 0 | 3 |
| Eosinophils, Above, Within | 2 | 3 | 2 | 4 |
| Eosinophils, Above, Above | 1 | 2 | 3 | 4 |
| Erythrocytes, Below, Below | 1 | 2 | 1 | 0 |
| Erythrocytes, Below, Within | 0 | 1 | 3 | 0 |
| Erythrocytes, Within, Below | 1 | 1 | 1 | 1 |
| Erythrocytes, Within, Within | 57 | 45 | 52 | 53 |
| Erythrocytes, Within, Above | 4 | 7 | 7 | 5 |
| Erythrocytes, Above, Within | 8 | 5 | 5 | 5 |
| Erythrocytes, Above, Above | 8 | 15 | 13 | 17 |
| Haematocrit, Below, Below | 4 | 0 | 0 | 1 |
| Haematocrit, Below, Within | 1 | 3 | 2 | 1 |
| Haematocrit, Within, Below | 2 | 2 | 2 | 4 |
| Haematocrit, Within, Within | 62 | 64 | 73 | 66 |
| Haematocrit, Within, Above | 0 | 1 | 1 | 2 |
| Haematocrit, Above, Within | 9 | 4 | 2 | 5 |
| Haematocrit, Above, Above | 1 | 2 | 2 | 2 |
| Haemoglobin, Below, Below | 7 | 3 | 4 | 3 |
| Haemoglobin, Below, Within | 5 | 3 | 4 | 2 |
| Haemoglobin, Within, Below | 4 | 9 | 2 | 5 |
| Haemoglobin, Within, Within | 58 | 58 | 68 | 67 |
| Haemoglobin, Within, Above | 0 | 1 | 2 | 0 |
| Haemoglobin, Above, Within | 4 | 1 | 0 | 3 |
| Haemoglobin, Above, Above | 1 | 1 | 2 | 1 |
| Lymphocytes, Below, Within | 0 | 0 | 0 | 1 |
| Lymphocytes, Within, Within | 51 | 54 | 58 | 51 |
| Lymphocytes, Within, Above | 2 | 3 | 6 | 3 |
| Lymphocytes, Above, Within | 7 | 9 | 8 | 14 |
| Lymphocytes, Above, Above | 19 | 10 | 10 | 12 |
| Monocytes, Within, Below | 0 | 0 | 0 | 1 |
| Monocytes, Within, Within | 50 | 53 | 51 | 50 |
| Monocytes, Within, Above | 23 | 16 | 19 | 18 |
| Monocytes, Above, Within | 2 | 1 | 4 | 5 |
| Monocytes, Above, Above | 4 | 6 | 8 | 7 |
| Neutrophils, Below, Below | 7 | 4 | 7 | 7 |
| Neutrophils, Below, Within | 7 | 6 | 6 | 6 |
| Neutrophils, Within, Below | 12 | 16 | 12 | 11 |
| Neutrophils, Within, Within | 52 | 49 | 56 | 56 |
| Neutrophils, Within, Above | 0 | 1 | 1 | 0 |
| Neutrophils, Above, Within | 1 | 0 | 0 | 1 |
| Platelets, Below, Above | 1 | 0 | 0 | 0 |
| Platelets, Within, Within | 12 | 19 | 14 | 18 |
| Platelets, Within, Above | 11 | 14 | 12 | 6 |
| Platelets, Above, Within | 14 | 10 | 15 | 16 |
| Platelets, Above, Above | 41 | 33 | 41 | 41 |
| WBC, Below, Below | 2 | 1 | 1 | 1 |
| WBC, Below, Within | 0 | 4 | 4 | 2 |
| WBC, Within, Below | 4 | 6 | 5 | 3 |
| WBC, Within, Within | 54 | 51 | 55 | 60 |
| WBC, Within, Above | 2 | 5 | 3 | 2 |
| WBC, Above, Within | 9 | 6 | 10 | 7 |
| WBC, Above, Above | 8 | 3 | 4 | 6 |
Panel tests include measures of ALT, AST, creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| ALT, Below, Below | 0 | 0 | 1 | 0 |
| ALT, Within, Within | 8 | 8 | 9 | 28 |
| ALT, Above, Within | 1 | 0 | 0 | 0 |
| AST, Within, Within | 8 | 8 | 9 | 28 |
| AST, Within, Above | 0 | 0 | 1 | 0 |
| AST, Above, Above | 1 | 0 | 0 | 0 |
| Creatinine, Below, Below | 9 | 8 | 10 | 28 |
| Potassium, Within, Within | — | — | 2 | 6 |
| Potassium, Within, Above | — | — | 4 | 3 |
| Potassium, Above, Within | — | — | 2 | 0 |
| Potassium, Above, Above | — | — | 2 | 1 |
| Sodium, Within, Within | — | — | 5 | 9 |
| Sodium, Within, Above | — | — | 2 | 1 |
| Sodium, Above, Within | — | — | 3 | 0 |
| Urea, Below, Below | — | — | 7 | 3 |
| Urea, Below, Within | — | — | 0 | 3 |
| Urea, Within, Below | — | — | 1 | 1 |
| Urea, Within, Within | — | — | 2 | 3 |
| Basophils, Within, Within | 1 | 3 | 6 | 12 |
| Basophils, Within, Above | 1 | 3 | 2 | 5 |
| Basophils, Above, Within | 0 | 1 | 1 | 1 |
| Basophils, Above, Above | 7 | 1 | 1 | 10 |
| Eosinophils, Within, Below | 0 | 0 | 0 | 1 |
| Eosinophils, Within, Within | 8 | 6 | 10 | 24 |
| Eosinophils, Within, Above | 1 | 0 | 0 | 1 |
| Eosinophils, Above, Within | 0 | 1 | 0 | 1 |
| Eosinophils, Above, Above | 0 | 1 | 0 | 1 |
| Erythrocytes, Below, Below | 0 | 0 | 0 | 1 |
| Erythrocytes, Within, Below | 0 | 0 | 0 | 1 |
| Erythrocytes, Within, Within | 6 | 5 | 7 | 19 |
| Erythrocytes, Within, Above | 1 | 1 | 0 | 1 |
| Erythrocytes, Above, Within | 0 | 0 | 1 | 2 |
| Erythrocytes, Above, Above | 2 | 2 | 2 | 4 |
| Haematocrit, Below, Below | 0 | 0 | 1 | 0 |
| Haematocrit, Below, Within | 1 | 0 | 0 | 0 |
| Haematocrit, Within, Below | 3 | 0 | 0 | 1 |
| Haematocrit, Within, Within | 5 | 5 | 8 | 21 |
| Haematocrit, Within, Above | 0 | 0 | 0 | 3 |
| Haematocrit, Above, Within | 0 | 3 | 0 | 2 |
| Haematocrit, Above, Above | 0 | 0 | 1 | 1 |
| Haemoglobin, Below, Below | 4 | 1 | 2 | 1 |
| Haemoglobin, Below, Within | 1 | 0 | 0 | 0 |
| Haemoglobin, Within, Below | 0 | 0 | 0 | 1 |
| Haemoglobin, Within, Within | 4 | 7 | 7 | 26 |
| Haemoglobin, Above, Above | 0 | 0 | 1 | 0 |
| Lymphocytes, Within, Within | 8 | 5 | 7 | 14 |
| Lymphocytes, Within, Above | 0 | 0 | 1 | 3 |
| Lymphocytes, Above, Within | 0 | 1 | 0 | 1 |
| Lymphocytes, Above, Above | 1 | 2 | 2 | 10 |
| Monocytes, Below, Within | 0 | 0 | 0 | 1 |
| Monocytes, Within, Below | 0 | 0 | 1 | 2 |
| Monocytes, Within, Within | 9 | 6 | 8 | 24 |
| Monocytes, Within, Above | 0 | 2 | 1 | 0 |
| Monocytes, Above, Above | 0 | 0 | 0 | 1 |
| Neutrophils, Below, Below | 1 | 0 | 1 | 1 |
| Neutrophils, Below, Within | 1 | 1 | 1 | 2 |
| Neutrophils, Below, Above | 0 | 1 | 0 | 0 |
| Neutrophils, Within, Below | 0 | 1 | 0 | 2 |
| Neutrophils, Within, Within | 7 | 5 | 8 | 22 |
| Neutrophils, Within, Above | 0 | 0 | 0 | 1 |
| Platelets, Within, Within | 1 | 2 | 2 | 7 |
| Platelets, Within, Above | 1 | 0 | 0 | 2 |
| Platelets, Above, Within | 0 | 0 | 0 | 4 |
| Platelets, Above, Above | 7 | 6 | 8 | 15 |
| WBC, Below, Below | 0 | 0 | 1 | 1 |
| WBC, Below, Within | 0 | 0 | 0 | 1 |
| WBC, Within, Within | 8 | 4 | 6 | 18 |
| WBC, Within, Above | 1 | 3 | 2 | 2 |
| WBC, Above, Within | 0 | 0 | 0 | 5 |
| WBC, Above, Above | 0 | 1 | 1 | 1 |
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| ALT, Below, Below | 0 | 1 | 0 | 0 |
| ALT, Below, Within | 0 | 0 | 1 | 0 |
| ALT, Within, Below | 0 | 0 | 0 | 2 |
| ALT, Within, Within | 70 | 68 | 71 | 68 |
| ALT, Within, Above | 2 | 2 | 0 | 3 |
| ALT, Above, Within | 0 | 1 | 2 | 0 |
| AST, Within, Within | 69 | 71 | 73 | 72 |
| AST, Within, Above | 2 | 1 | 0 | 0 |
| AST, Above, Within | 1 | 0 | 0 | 0 |
| AST, Above, Above | 0 | 0 | 1 | 1 |
| Creatinine, Below, Below | 72 | 71 | 74 | 72 |
| Creatinine, Below, Within | 0 | 1 | 0 | 1 |
| Potassium, Within, Within | 18 | 16 | 18 | 19 |
| Potassium, Within, Above | 24 | 26 | 34 | 28 |
| Potassium, Above, Within | 9 | 8 | 2 | 10 |
| Potassium, Above, Above | 21 | 22 | 20 | 16 |
| Sodium, Within, Within | 48 | 53 | 54 | 52 |
| Sodium, Within, Above | 7 | 5 | 8 | 8 |
| Sodium, Above, Within | 17 | 11 | 10 | 13 |
| Sodium, Above, Above | 0 | 3 | 2 | 0 |
| Urea, Below, Below | 27 | 24 | 32 | 24 |
| Urea, Below, Within | 9 | 12 | 7 | 11 |
| Urea, Below, Above | 0 | 1 | 0 | 0 |
| Urea, Within, Below | 13 | 15 | 13 | 13 |
| Urea, Within, Within | 23 | 20 | 22 | 25 |
| Basophils, Below, Within | 0 | 1 | 0 | 0 |
| Basophils, Within, Below | 0 | 0 | 0 | 2 |
| Basophils, Within, Within | 58 | 58 | 64 | 54 |
| Basophils, Within, Above | 8 | 3 | 7 | 8 |
| Basophils, Above, Within | 5 | 5 | 2 | 5 |
| Basophils, Above, Above | 1 | 5 | 1 | 4 |
| Eosinophils, Below, Within | 0 | 0 | 1 | 0 |
| Eosinophils, Within, Below | 1 | 2 | 1 | 1 |
| Eosinophils, Within, Within | 61 | 60 | 62 | 61 |
| Eosinophils, Within, Above | 2 | 1 | 2 | 4 |
| Eosinophils, Above, Within | 6 | 0 | 1 | 2 |
| Eosinophils, Above, Above | 2 | 9 | 7 | 5 |
| Erythrocytes, Below, Within | 1 | 1 | 0 | 0 |
| Erythrocytes, Within, Below | 0 | 0 | 2 | 0 |
| Erythrocytes, Within, Within | 48 | 45 | 44 | 50 |
| Erythrocytes, Within, Above | 5 | 2 | 5 | 3 |
| Erythrocytes, Above, Within | 5 | 3 | 4 | 7 |
| Erythrocytes, Above, Above | 13 | 21 | 19 | 13 |
| Haematocrit, Below, Below | 1 | 0 | 1 | 2 |
| Haematocrit, Below, Within | 1 | 2 | 0 | 0 |
| Haematocrit, Within, Below | 3 | 2 | 2 | 3 |
| Haematocrit, Within, Within | 60 | 60 | 57 | 62 |
| Haematocrit, Within, Above | 4 | 0 | 5 | 1 |
| Haematocrit, Above, Within | 0 | 5 | 3 | 2 |
| Haematocrit, Above, Above | 3 | 3 | 6 | 3 |
| Haemoglobin, Below, Below | 7 | 7 | 5 | 4 |
| Haemoglobin, Below, Within | 2 | 3 | 1 | 1 |
| Haemoglobin, Within, Below | 5 | 2 | 4 | 7 |
| Haemoglobin, Within, Within | 54 | 56 | 59 | 57 |
| Haemoglobin, Within, Above | 1 | 1 | 1 | 1 |
| Haemoglobin, Above, Within | 2 | 2 | 1 | 2 |
| Haemoglobin, Above, Above | 1 | 1 | 3 | 1 |
| Lymphocytes, Within, Below | 0 | 0 | 0 | 1 |
| Lymphocytes, Within, Within | 38 | 43 | 44 | 36 |
| Lymphocytes, Within, Above | 13 | 11 | 11 | 9 |
| Lymphocytes, Above, Within | 6 | 5 | 10 | 11 |
| Lymphocytes, Above, Above | 15 | 13 | 9 | 16 |
| Monocytes, Below, Within | 1 | 0 | 0 | 0 |
| Monocytes, Within, Below | 0 | 0 | 0 | 2 |
| Monocytes, Within, Within | 52 | 47 | 60 | 62 |
| Monocytes, Within, Above | 7 | 15 | 8 | 2 |
| Monocytes, Above, Within | 9 | 7 | 3 | 4 |
| Monocytes, Above, Above | 3 | 3 | 3 | 3 |
| Neutrophils, Below, Below | 1 | 1 | 3 | 5 |
| Neutrophils, Below, Within | 6 | 7 | 11 | 6 |
| Neutrophils, Within, Below | 5 | 7 | 3 | 2 |
| Neutrophils, Within, Within | 57 | 53 | 54 | 60 |
| Neutrophils, Within, Above | 2 | 2 | 1 | 0 |
| Neutrophils, Above, Within | 1 | 2 | 1 | 0 |
| Neutrophils, Above, Above | 0 | 0 | 1 | 0 |
| Platelets, Within, Within | 9 | 15 | 11 | 15 |
| Platelets, Within, Above | 10 | 14 | 16 | 5 |
| Platelets, Above, Below | 1 | 0 | 0 | 0 |
| Platelets, Above, Within | 8 | 6 | 7 | 7 |
| Platelets, Above, Above | 44 | 37 | 40 | 46 |
| WBC, Below, Within | 3 | 1 | 2 | 2 |
| WBC, Within, Below | 3 | 1 | 1 | 3 |
| WBC, Within, Within | 47 | 48 | 56 | 53 |
| WBC, Within, Above | 6 | 9 | 5 | 7 |
| WBC, Above, Within | 5 | 6 | 3 | 2 |
| WBC, Above, Above | 8 | 7 | 7 | 6 |
Panel tests include measures of ALT, AST, creatinine, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and WBC. Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| ALT, Within, Within | 9 | 8 | 9 | 27 |
| ALT, Above, Above | 0 | 0 | 0 | 1 |
| AST, Within, Within | 9 | 8 | 9 | 28 |
| Creatinine, Below, Below | 8 | 8 | 9 | 28 |
| Creatinine, Within, Below | 1 | 0 | 0 | 0 |
| Potassium, Within, Within | 1 | 3 | 3 | 11 |
| Potassium, Within, Above | 3 | 1 | 0 | 5 |
| Potassium, Above, Within | 1 | 1 | 3 | 7 |
| Potassium, Above, Above | 4 | 3 | 3 | 5 |
| Sodium, Within, Within | 4 | 8 | 6 | 18 |
| Sodium, Within, Above | 2 | 0 | 0 | 2 |
| Sodium, Above, Within | 1 | 0 | 3 | 5 |
| Sodium, Above, Above | 2 | 0 | 0 | 3 |
| Urea, Below, Below | 3 | 2 | 5 | 9 |
| Urea, Below, Within | 3 | 1 | 1 | 2 |
| Urea, Within, Below | 1 | 1 | 1 | 4 |
| Urea, Within, Within | 2 | 4 | 2 | 13 |
| Basophils, Within, Within | 5 | 7 | 8 | 23 |
| Basophils, Within, Above | 2 | 0 | 0 | 3 |
| Basophils, Above, Within | 2 | 0 | 1 | 2 |
| Basophils, Above, Above | 0 | 1 | 0 | 0 |
| Eosinophils, Below, Within | 0 | 0 | 0 | 2 |
| Eosinophils, Within, Within | 8 | 7 | 9 | 22 |
| Eosinophils, Within, Above | 1 | 0 | 0 | 1 |
| Eosinophils, Above, Above | 0 | 1 | 0 | 3 |
| Erythrocytes, Below, Below | 0 | 0 | 0 | 1 |
| Erythrocytes, Within, Within | 6 | 4 | 7 | 20 |
| Erythrocytes, Within, Above | 1 | 1 | 0 | 0 |
| Erythrocytes, Above, Within | 1 | 2 | 2 | 3 |
| Erythrocytes, Above, Above | 1 | 1 | 0 | 4 |
| Haematocrit, Below, Below | 0 | 0 | 0 | 2 |
| Haematocrit, Below, Within | 0 | 0 | 0 | 1 |
| Haematocrit, Within, Within | 7 | 6 | 8 | 16 |
| Haematocrit, Within, Above | 1 | 1 | 0 | 2 |
| Haematocrit, Above, Within | 1 | 1 | 0 | 2 |
| Haematocrit, Above, Above | 0 | 0 | 1 | 5 |
| Haemoglobin, Below, Below | 0 | 0 | 2 | 3 |
| Haemoglobin, Below, Within | 0 | 0 | 0 | 2 |
| Haemoglobin, Within, Below | 1 | 0 | 0 | 1 |
| Haemoglobin, Within, Within | 8 | 8 | 6 | 17 |
| Haemoglobin, Within, Above | 0 | 0 | 0 | 2 |
| Haemoglobin, Above, Within | 0 | 0 | 0 | 2 |
| Haemoglobin, Above, Above | 0 | 0 | 1 | 1 |
| Lymphocytes, Within, Within | 6 | 6 | 6 | 21 |
| Lymphocytes, Within, Above | 2 | 1 | 0 | 2 |
| Lymphocytes, Above, Within | 1 | 1 | 1 | 2 |
| Lymphocytes, Above, Above | 0 | 0 | 2 | 3 |
| Monocytes, Below, Within | 1 | 0 | 0 | 2 |
| Monocytes, Within, Below | 0 | 0 | 1 | 0 |
| Monocytes, Within, Within | 7 | 8 | 6 | 22 |
| Monocytes, Within, Above | 1 | 0 | 2 | 2 |
| Monocytes, Above, Within | 0 | 0 | 0 | 1 |
| Monocytes, Above, Above | 0 | 0 | 0 | 1 |
| Neutrophils, Below, Below | 0 | 0 | 0 | 1 |
| Neutrophils, Below, Within | 0 | 1 | 2 | 1 |
| Neutrophils, Within, Below | 1 | 0 | 1 | 2 |
| Neutrophils, Within, Within | 8 | 5 | 6 | 24 |
| Neutrophils, Within, Above | 0 | 2 | 0 | 0 |
| Platelets, Below, Within | 0 | 1 | 0 | 0 |
| Platelets, Within, Within | 2 | 2 | 2 | 6 |
| Platelets, Within, Above | 0 | 0 | 3 | 5 |
| Platelets, Above, Within | 2 | 1 | 2 | 5 |
| Platelets, Above, Above | 5 | 4 | 2 | 12 |
| WBC, Below, Below | 0 | 0 | 1 | 0 |
| WBC, Below, Within | 1 | 2 | 2 | 0 |
| WBC, Within, Below | 0 | 0 | 0 | 3 |
| WBC, Within, Within | 7 | 4 | 3 | 18 |
| WBC, Within, Above | 1 | 1 | 2 | 3 |
| WBC, Above, Within | 0 | 1 | 0 | 3 |
| WBC, Above, Above | 0 | 0 | 1 | 1 |
Panel tests include measures of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, potassium, sodium, urea, basophils, eosinophils, erythrocytes, haematocrit, haemoglobin, lymphocytes, monocytes, neutrophils, platelets and white blood cells (WBC). Categories reported when comparing Day 1 (baseline) and normal range hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>,\<range at baseline\>,\<range at timing\>, where range is being classified as Below = value below; Within = value within; and Above = value above the laboratory reference range defined for the specified visit and laboratory parameter.
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| ALT, Below, Within | 1 | 2 | 1 | 2 |
| ALT, Within, Below | 2 | 1 | 0 | 0 |
| ALT, Within, Within | 64 | 67 | 69 | 65 |
| ALT, Within, Above | 1 | 0 | 3 | 0 |
| ALT, Above, Within | 1 | 1 | 0 | 0 |
| ALT, Above, Above | 0 | 0 | 0 | 4 |
| AST, Within, Within | 68 | 71 | 71 | 70 |
| AST, Within, Above | 1 | 0 | 1 | 0 |
| AST, Above, Within | 0 | 0 | 1 | 0 |
| AST, Above, Above | 0 | 0 | 0 | 1 |
| Creatinine, Below, Below | 68 | 70 | 73 | 71 |
| Creatinine, Below, Within | 0 | 1 | 0 | 0 |
| Creatinine, Within, Below | 1 | 0 | 0 | 0 |
| Potassium, Within, Within | 26 | 28 | 25 | 21 |
| Potassium, Within, Above | 12 | 18 | 23 | 23 |
| Potassium, Above, Within | 11 | 8 | 7 | 10 |
| Potassium, Above, Above | 20 | 17 | 18 | 17 |
| Sodium, Below, Within | 1 | 2 | 4 | 2 |
| Sodium, Within, Below | 0 | 0 | 1 | 0 |
| Sodium, Within, Within | 55 | 61 | 55 | 63 |
| Sodium, Within, Above | 4 | 4 | 7 | 2 |
| Sodium, Above, Within | 8 | 3 | 6 | 4 |
| Sodium, Above, Above | 1 | 1 | 0 | 0 |
| Urea, Below, Below | 18 | 15 | 16 | 13 |
| Urea, Below, Within | 12 | 6 | 11 | 12 |
| Urea, Within, Below | 10 | 14 | 14 | 5 |
| Urea, Within, Within | 29 | 36 | 32 | 41 |
| Basophils, Below, Within | 0 | 0 | 0 | 1 |
| Basophils, Within, Within | 53 | 54 | 62 | 53 |
| Basophils, Within, Above | 7 | 8 | 4 | 8 |
| Basophils, Above, Within | 6 | 6 | 6 | 3 |
| Basophils, Above, Above | 3 | 3 | 1 | 6 |
| Eosinophils, Below, Within | 1 | 1 | 0 | 3 |
| Eosinophils, Within, Below | 0 | 2 | 2 | 0 |
| Eosinophils, Within, Within | 59 | 58 | 59 | 56 |
| Eosinophils, Within, Above | 2 | 4 | 2 | 2 |
| Eosinophils, Above, Within | 2 | 1 | 3 | 3 |
| Eosinophils, Above, Above | 5 | 5 | 7 | 7 |
| Erythrocytes, Below, Below | 0 | 1 | 0 | 0 |
| Erythrocytes, Within, Within | 44 | 39 | 46 | 44 |
| Erythrocytes, Within, Above | 4 | 5 | 5 | 5 |
| Erythrocytes, Above, Within | 8 | 2 | 4 | 5 |
| Erythrocytes, Above, Above | 13 | 24 | 18 | 17 |
| Haematocrit, Below, Below | 2 | 2 | 0 | 0 |
| Haematocrit, Below, Within | 1 | 1 | 0 | 1 |
| Haematocrit, Within, Below | 0 | 1 | 0 | 0 |
| Haematocrit, Within, Within | 55 | 55 | 56 | 57 |
| Haematocrit, Within, Above | 1 | 7 | 9 | 1 |
| Haematocrit, Above, Within | 5 | 2 | 2 | 7 |
| Haematocrit, Above, Above | 5 | 3 | 6 | 5 |
| Haemoglobin, Below, Below | 6 | 4 | 4 | 4 |
| Haemoglobin, Below, Within | 3 | 3 | 0 | 3 |
| Haemoglobin, Within, Below | 2 | 5 | 2 | 1 |
| Haemoglobin, Within, Within | 53 | 52 | 57 | 59 |
| Haemoglobin, Within, Above | 1 | 2 | 4 | 1 |
| Haemoglobin, Above, Within | 2 | 1 | 4 | 2 |
| Haemoglobin, Above, Above | 2 | 4 | 2 | 1 |
| Lymphocytes, Within, Within | 43 | 57 | 58 | 48 |
| Lymphocytes, Within, Above | 13 | 6 | 5 | 8 |
| Lymphocytes, Above, Within | 4 | 3 | 8 | 8 |
| Lymphocytes, Above, Above | 9 | 5 | 2 | 7 |
| Monocytes, Below, Below | 1 | 0 | 0 | 0 |
| Monocytes, Below, Within | 1 | 0 | 2 | 1 |
| Monocytes, Within, Below | 1 | 1 | 0 | 2 |
| Monocytes, Within, Within | 54 | 61 | 63 | 62 |
| Monocytes, Within, Above | 7 | 3 | 5 | 3 |
| Monocytes, Above, Within | 4 | 4 | 2 | 2 |
| Monocytes, Above, Above | 1 | 2 | 1 | 1 |
| Neutrophils, Below, Below | 5 | 1 | 0 | 1 |
| Neutrophils, Below, Within | 4 | 5 | 9 | 6 |
| Neutrophils, Within, Below | 3 | 3 | 5 | 5 |
| Neutrophils, Within, Within | 55 | 60 | 58 | 58 |
| Neutrophils, Within, Above | 1 | 0 | 0 | 1 |
| Neutrophils, Above, Within | 1 | 2 | 1 | 0 |
| Platelets, Below, Below | 0 | 0 | 1 | 0 |
| Platelets, Below, Within | 0 | 0 | 1 | 0 |
| Platelets, Within, Within | 17 | 21 | 19 | 16 |
| Platelets, Within, Above | 10 | 18 | 17 | 11 |
| Platelets, Above, Within | 8 | 7 | 8 | 6 |
| Platelets, Above, Above | 34 | 25 | 27 | 38 |
| WBC, Below, Below | 1 | 0 | 2 | 0 |
| WBC, Below, Within | 4 | 3 | 6 | 2 |
| WBC, Within, Below | 1 | 2 | 1 | 0 |
| WBC, Within, Within | 44 | 51 | 53 | 53 |
| WBC, Within, Above | 6 | 6 | 2 | 6 |
| WBC, Above, Within | 4 | 7 | 6 | 6 |
| WBC, Above, Above | 9 | 2 | 3 | 4 |
Anti-serotype specific Shigella LPS/OAg serum IgG GMCs were measured by ELISA and expressed in EU/mL of serum. S. sonnei, S. flexneri 1b, S. flexneri 2a, and S. flexneri 3a serotypes were tested.
| EU/mL | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| S sonnei Ab IgG, Day 1 | 15.3 (10.8 to 21.8) | 8.9 (6.9 to 11.5) | 21.0 (13.2 to 33.6) |
| S sonnei Ab IgG, Day 15 | 307.5 (167.3 to 565.2) | 170.7 (98.2 to 296.5) | 18.4 (11.6 to 29.3) |
| S sonnei Ab IgG, Day 29 | 325.3 (181.6 to 582.8) | 172.1 (96.7 to 306.4) | 18.1 (11.5 to 28.6) |
| S sonnei Ab IgG, Day 85 | 287.6 (144.1 to 574.1) | — | — |
| S sonnei Ab IgG, Day 169 | — | 94.8 (55.2 to 162.9) | — |
| S sonnei Ab IgG, Day 85/169 | — | — | 19.0 (11.1 to 32.3) |
| S sonnei Ab IgG, Day 113 | 387.8 (206.6 to 727.8) | — | — |
| S sonnei Ab IgG, Day 197 | — | 167.2 (104.3 to 267.9) | — |
| S sonnei Ab IgG, Day 113/197 | — | — | 19.9 (11.8 to 33.7) |
| S flexneri 1b Ab IgG, Day 1 | 23.5 (13.6 to 40.5) | 22.9 (13.9 to 37.8) | 26.9 (15.3 to 47.3) |
| S flexneri 1b Ab IgG, Day 15 | 123.1 (71.8 to 211.1) | 102.1 (63.8 to 163.5) | 27.4 (16.1 to 46.7) |
| S flexneri 1b Ab IgG, Day 29 | 118.3 (70.5 to 198.5) | 90.2 (55.9 to 145.5) | 27.0 (15.8 to 46.3) |
| S flexneri 1b Ab IgG, Day 85 | 79.1 (45.3 to 138.1) | — | — |
| S flexneri 1b Ab IgG, Day 169 | — | 48.5 (30.1 to 78.0) | — |
| S flexneri 1b Ab IgG, Day 85/169 | — | — | 27.2 (15.5 to 47.7) |
| S flexneri 1b Ab IgG, Day 113 | 129.7 (79.6 to 211.5) | — | — |
| S flexneri 1b Ab IgG, Day 197 | — | 73.0 (48.6 to 109.7) | — |
| S flexneri 1b Ab IgG, Day 113/197 | — | — | 26.1 (14.6 to 46.9) |
| S flexneri 2a Ab IgG, Day 1 | 33.3 (23.1 to 47.9) | 32.7 (22.2 to 48.2) | 44.5 (27.3 to 72.6) |
| S flexneri 2a Ab IgG, Day 15 | 608.0 (432.4 to 854.9) | 635.2 (459.5 to 878.1) | 44.3 (27.4 to 71.6) |
| S flexneri 2a Ab IgG, Day 29 | 545.8 (393.1 to 757.6) | 582.6 (424.1 to 800.4) | 42.8 (26.3 to 69.5) |
| S flexneri 2a Ab IgG, Day 85 | 411.8 (300.4 to 564.6) | — | — |
| S flexneri 2a Ab IgG, Day 169 | — | 364.9 (259.9 to 512.5) | — |
| S flexneri 2a Ab IgG, Day 85/169 | — | — | 41.4 (23.3 to 73.6) |
| S flexneri 2a Ab IgG, Day 113 | 473.6 (351.1 to 638.8) | — | — |
| S flexneri 2a Ab IgG, Day 197 | — | 451.0 (327.8 to 620.6) | — |
| S flexneri 2a Ab IgG, Day 113/197 | — | — | 43.8 (25.1 to 76.3) |
| S flexneri 3a Ab IgG, Day 1 | 17.3 (11.1 to 27.0) | 14.2 (8.4 to 23.9) | 19.9 (13.1 to 30.2) |
| S flexneri 3a Ab IgG, Day 15 | 59.1 (40.5 to 86.1) | 63.8 (36.2 to 112.4) | 18.4 (12.2 to 27.8) |
| S flexneri 3a Ab IgG, Day 29 | 56.7 (37.6 to 85.4) | 60.6 (34.8 to 105.5) | 19.3 (12.7 to 29.4) |
| S flexneri 3a Ab IgG, Day 85 | 26.9 (16.7 to 43.4) | — | — |
| S flexneri 3a Ab IgG, Day 169 | — | 24.7 (14.1 to 43.2) | — |
| S flexneri 3a Ab IgG, Day 85/169 | — | — | 10.1 (6.4 to 15.9) |
| S flexneri 3a Ab IgG, Day 113 | 43.1 (26.9 to 69.2) | — | — |
| S flexneri 3a Ab IgG, Day 197 | — | 37.2 (22.4 to 61.7) | — |
| S flexneri 3a Ab IgG, Day 113/197 | — | — | 9.2 (5.6 to 15.0) |
| EU/mL | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| S sonnei Ab IgG, Day 1 | 166.4 (82.8 to 334.2) | 171.2 (65.0 to 450.6) |
| S sonnei Ab IgG, Day 29 | 3112.0 (2181.6 to 4439.2) | 172.0 (66.7 to 443.6) |
| S sonnei Ab IgG, Day 85 | 2046.5 (1372.1 to 3052.5) | 182.1 (73.2 to 453.1) |
| S sonnei Ab IgG, Day 113 | 1974.4 (1288.5 to 3025.6) | 172.3 (68.8 to 431.6) |
| S flexneri 1b Ab IgG, Day 1 | 194.7 (44.0 to 862.2) | 106.4 (41.0 to 276.2) |
| S flexneri 1b Ab IgG, Day 29 | 388.5 (98.6 to 1531.3) | 103.3 (40.2 to 265.8) |
| S flexneri 1b Ab IgG, Day 85 | 328.0 (84.8 to 1268.8) | 110.8 (38.9 to 315.5) |
| S flexneri 1b Ab IgG, Day 113 | 358.3 (98.6 to 1301.7) | 107.2 (37.5 to 306.1) |
| S flexneri 2a Ab IgG, Day 1 | 192.3 (93.7 to 394.6) | 155.8 (70.7 to 343.6) |
| S flexneri 2a Ab IgG, Day 29 | 563.0 (269.1 to 1177.7) | 146.1 (68.7 to 311.0) |
| S flexneri 2a Ab IgG, Day 85 | 463.0 (220.3 to 973.4) | 158.1 (67.7 to 369.3) |
| S flexneri 2a Ab IgG, Day 113 | 538.6 (269.9 to 1074.7) | 154.0 (68.5 to 346.2) |
| S flexneri 3a Ab IgG, Day 1 | 84.8 (34.5 to 208.8) | 61.3 (19.6 to 192.0) |
| S flexneri 3a Ab IgG, Day 29 | 212.8 (89.9 to 503.6) | 57.4 (18.2 to 181.5) |
| S flexneri 3a Ab IgG, Day 85 | 174.4 (75.1 to 405.3) | 62.3 (16.7 to 233.3) |
| S flexneri 3a Ab IgG, Day 113 | 225.4 (103.2 to 492.7) | 61.6 (16.7 to 226.8) |
| EU/mL | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| S sonnei Ab IgG, Day 1 | 22.7 (8.5 to 61.0) | 39.1 (9.5 to 160.1) | 20.7 (10.5 to 41.0) |
| S sonnei Ab IgG, Day 29 | 899.0 (122.7 to 6588.6) | 746.9 (93.9 to 5940.9) | 19.3 (10.4 to 35.8) |
| S sonnei Ab IgG, Day 85) | 702.7 (125.7 to 3927.4) | 388.2 (56.6 to 2663.4) | 24.7 (11.1 to 54.7) |
| S sonnei Ab IgG, Day 113 | 1163.2 (289.8 to 4668.7) | 560.2 (86.0 to 3651.0) | 40.2 (15.9 to 101.6) |
| S flexneri 1b Ab IgG, Day 1 | 28.6 (6.6 to 123.1) | 38.4 (7.0 to 211.4) | 37.0 (16.4 to 83.3) |
| S flexneri 1b Ab IgG, Day 29 | 74.0 (23.3 to 234.8) | 119.4 (27.2 to 525.1) | 33.4 (13.6 to 81.7) |
| S flexneri 1b Ab IgG, Day 85 | 39.3 (10.7 to 144.5) | 65.4 (13.1 to 326.7) | 34.5 (15.0 to 79.6) |
| S flexneri 1b Ab IgG, Day 113 | 66.7 (20.5 to 217.0) | 100.3 (21.6 to 466.4) | 31.9 (14.0 to 72.4) |
| S flexneri 2a Ab IgG, Day 1 | 24.5 (5.1 to 117.9) | 21.0 (4.7 to 93.0) | 30.9 (12.4 to 77.3) |
| S flexneri 2a Ab IgG, Day 29 | 219.2 (65.6 to 732.9) | 193.5 (76.2 to 491.6) | 30.6 (12.7 to 74.2) |
| S flexneri 2a Ab IgG, Day 85 | 101.2 (28.7 to 356.9) | 103.8 (36.3 to 297.0) | 32.1 (14.2 to 72.5) |
| S flexneri 2a Ab IgG, Day 113 | 267.3 (101.0 to 707.4) | 290.0 (115.0 to 731.3) | 29.5 (13.8 to 63.2) |
| S flexneri 3a Ab IgG, Day 1 | 14.2 (4.5 to 44.7) | 8.5 (3.5 to 20.6) | 7.6 (3.0 to 19.8) |
| S flexneri 3a Ab IgG, Day 29 | 30.7 (10.7 to 87.9) | 22.0 (7.6 to 63.7) | 6.2 (2.5 to 15.2) |
| S flexneri 3a Ab IgG, Day 85 | 17.8 (5.9 to 53.4) | 14.1 (4.9 to 40.3) | 6.2 (2.7 to 14.2) |
| S flexneri 3a Ab IgG, Day 113 | 32.1 (12.3 to 84.2) | 26.1 (10.2 to 66.7) | 7.0 (3.2 to 15.6) |
| EU/mL | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| S sonnei Ab IgG, Day 1 | 6.4 (6.4 to 6.4) | 6.9 (5.8 to 8.1) | 6.4 (6.4 to 6.4) | 6.6 (6.2 to 6.9) |
| S sonnei Ab IgG, Day 29 | 16.9 (7.8 to 36.6) | 17.5 (9.5 to 32.4) | 17.3 (9.1 to 33.0) | 6.4 (6.4 to 6.4) |
| S sonnei Ab IgG, Day 85 | 27.2 (12.6 to 58.3) | 32.7 (16.1 to 66.6) | 23.3 (11.1 to 48.9) | 6.4 (6.4 to 6.4) |
| S sonnei Ab IgG, Day 113 | 240.4 (60.3 to 958.3) | 264.7 (105.1 to 666.9) | 171.0 (67.7 to 431.6) | 6.4 (6.4 to 6.4) |
| S sonnei Ab IgG, Day 253 | 128.5 (60.1 to 274.9) | 99.5 (50.4 to 196.3) | 63.4 (24.4 to 165.1) | 6.4 (6.4 to 6.4) |
| S sonnei Ab IgG, Day 281 | 429.9 (155.7 to 1186.8) | 275.8 (90.1 to 844.3) | 185.2 (111.2 to 308.4) | 6.4 (6.4 to 6.4) |
| S flexneri 1b Ab IgG, Day 1 | 6.0 (2.5 to 14.8) | 6.4 (3.9 to 10.6) | 4.2 (2.4 to 7.4) | 5.9 (4.1 to 8.5) |
| S flexneri 1b Ab IgG, Day 29 | 24.2 (8.2 to 71.2) | 18.5 (10.6 to 32.3) | 7.0 (3.1 to 16.0) | 6.3 (4.6 to 8.6) |
| S flexneri 1b Ab IgG, Day 85 | 16.3 (6.7 to 40.0) | 9.4 (4.9 to 17.8) | 6.3 (3.1 to 12.7) | 7.4 (5.0 to 10.9) |
| S flexneri 1b Ab IgG, Day 113 | 30.5 (8.6 to 108.0) | 18.2 (12.1 to 27.5) | 14.2 (5.0 to 40.2) | 7.4 (5.0 to 10.9) |
| S flexneri 1b Ab IgG, Day 253 | 9.0 (3.5 to 23.2) | 7.2 (3.2 to 16.1) | 8.9 (4.5 to 17.3) | 7.4 (5.0 to 10.9) |
| S flexneri 1b Ab IgG, Day 281 | 23.3 (9.5 to 57.0) | 20.4 (8.1 to 51.2) | 29.4 (15.3 to 56.6) | 8.0 (5.3 to 12.0) |
| S flexneri 2a Ab IgG, Day 1 | 3.6 (1.5 to 9.0) | 4.4 (2.3 to 8.3) | 3.9 (1.8 to 8.4) | 4.1 (2.2 to 7.4) |
| S flexneri 2a Ab IgG, Day 29 | 34.6 (11.0 to 109.1) | 40.5 (16.3 to 100.6) | 17.1 (6.0 to 49.0) | 4.6 (2.5 to 8.4) |
| S flexneri 2a Ab IgG, Day 85 | 29.6 (11.5 to 76.6) | 16.4 (7.4 to 36.3) | 9.7 (3.8 to 24.7) | 5.8 (3.2 to 10.6) |
| S flexneri 2a Ab IgG, Day 113 | 81.6 (38.9 to 171.1) | 77.4 (31.1 to 192.5) | 65.5 (33.0 to 130.0) | 7.2 (3.6 to 14.2) |
| S flexneri 2a Ab IgG, Day 253 | 9.9 (2.5 to 38.8) | 11.2 (2.7 to 47.6) | 14.4 (5.2 to 40.1) | 7.7 (3.9 to 15.2) |
| S flexneri 2a Ab IgG, Day 281 | 135.0 (81.6 to 223.1) | 72.5 (24.6 to 213.7) | 110.7 (60.4 to 203.0) | 8.2 (4.4 to 15.2) |
| S flexneri 3a Ab IgG, Day 1 | 2.7 (1.3 to 5.6) | 5.1 (2.7 to 9.7) | 2.6 (1.4 to 4.7) | 3.3 (2.2 to 5.0) |
| S flexneri 3a Ab IgG, Day 29 | 9.6 (3.4 to 26.9) | 8.9 (3.1 to 25.2) | 3.5 (1.7 to 7.3) | 3.4 (2.2 to 5.2) |
| S flexneri 3a Ab IgG, Day 85 | 5.1 (2.2 to 12.2) | 6.0 (2.4 to 15.1) | 2.1 (1.1 to 4.2) | 4.0 (2.5 to 6.4) |
| S flexneri 3a Ab IgG, Day 113 | 12.5 (4.0 to 38.4) | 7.9 (2.5 to 25.1) | 4.5 (2.3 to 8.8) | 3.8 (2.4 to 5.8) |
| S flexneri 3a Ab IgG, Day 253 | 6.8 (2.4 to 19.2) | 8.5 (2.0 to 35.6) | 3.2 (1.6 to 6.5) | 4.5 (2.8 to 7.0) |
| S flexneri 3a Ab IgG, Day 281 | 23.0 (7.0 to 75.8) | 20.4 (5.2 to 79.7) | 13.2 (3.5 to 49.8) | 4.9 (3.1 to 7.9) |
| EU/mL | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| S sonnei Ab IgG, Day 1 | 10.9 (8.9 to 13.2) | 9.5 (8.1 to 11.0) | 10.7 (8.7 to 13.3) | 9.8 (8.2 to 11.6) |
| S sonnei Ab IgG, Day 29 | 36.0 (27.4 to 47.4) | 41.9 (33.6 to 52.4) | 38.5 (29.0 to 51.3) | 9.5 (8.1 to 11.1) |
| S sonnei Ab IgG, Day 85 | 41.7 (32.3 to 53.9) | 46.7 (36.8 to 59.2) | 41.1 (33.5 to 50.6) | 8.2 (6.9 to 9.7) |
| S sonnei Ab IgG, Day 113 | 313.6 (224.5 to 438.1) | 353.4 (244.7 to 510.4) | 328.7 (235.4 to 459.1) | 9.0 (7.2 to 11.3) |
| S sonnei Ab IgG, Day 253 | 162.1 (128.9 to 203.8) | 195.3 (154.9 to 246.2) | 219.0 (164.3 to 291.8) | 16.9 (12.5 to 22.8) |
| S sonnei Ab IgG, Day 281 | 446.3 (342.1 to 582.3) | 535.1 (416.2 to 688.0) | 603.8 (461.4 to 790.2) | 18.6 (13.7 to 25.2) |
| S flexneri 1b Ab IgG, Day 1 | 11.4 (8.5 to 15.4) | 11.8 (8.7 to 15.9) | 12.6 (9.1 to 17.3) | 13.4 (9.9 to 18.0) |
| S flexneri 1b Ab IgG, Day 29 | 32.9 (23.7 to 45.6) | 47.5 (34.8 to 64.9) | 36.8 (26.5 to 51.0) | 13.4 (10.0 to 18.0) |
| S flexneri 1b Ab IgG, Day 85 | 13.0 (9.9 to 17.0) | 11.1 (8.5 to 14.4) | 9.6 (7.5 to 12.3) | 8.1 (6.2 to 10.7) |
| S flexneri 1b Ab IgG, Day 113 | 25.4 (18.5 to 34.8) | 21.2 (17.4 to 25.8) | 20.6 (16.4 to 25.8) | 7.4 (5.7 to 9.5) |
| S flexneri 1b Ab IgG, Day 253 | 15.7 (11.6 to 21.3) | 9.3 (7.4 to 11.7) | 10.3 (7.8 to 13.5) | 16.9 (11.7 to 24.2) |
| S flexneri 1b Ab IgG, Day 281 | 57.3 (43.2 to 76.0) | 34.4 (26.6 to 44.3) | 36.7 (28.1 to 47.9) | 16.6 (11.5 to 23.9) |
| S flexneri 2a Ab IgG, Day 1 | 6.1 (4.6 to 8.2) | 5.2 (4.0 to 6.6) | 6.2 (4.7 to 8.2) | 5.7 (4.4 to 7.5) |
| S flexneri 2a Ab IgG, Day 29 | 51.6 (38.1 to 69.9) | 58.2 (42.6 to 79.5) | 59.4 (42.2 to 83.7) | 6.2 (4.7 to 8.2) |
| S flexneri 2a Ab IgG, Day 85 | 20.0 (14.0 to 28.6) | 12.7 (9.2 to 17.7) | 14.4 (10.1 to 20.6) | 4.7 (3.2 to 6.7) |
| S flexneri 2a Ab IgG, Day 113 | 95.4 (72.4 to 125.5) | 69.9 (52.2 to 93.7) | 84.4 (62.4 to 114.2) | 4.5 (3.2 to 6.4) |
| S flexneri 2a Ab IgG, Day 253 | 27.5 (19.9 to 38.1) | 19.5 (15.3 to 25.0) | 23.2 (18.0 to 30.0) | 11.8 (8.2 to 17.1) |
| S flexneri 2a Ab IgG, Day 281 | 189.2 (139.2 to 257.2) | 142.3 (112.6 to 179.7) | 177.9 (134.7 to 234.9) | 12.1 (8.3 to 17.4) |
| S flexneri 3a Ab IgG, Day 1 | 8.1 (5.3 to 12.5) | 5.4 (3.7 to 7.9) | 6.3 (4.1 to 9.6) | 10.2 (6.6 to 15.8) |
| S flexneri 3a Ab IgG, Day 29 | 22.4 (15.2 to 33.0) | 19.1 (12.8 to 28.5) | 14.8 (9.7 to 22.6) | 10.0 (6.3 to 15.8) |
| S flexneri 3a Ab IgG, Day 85 | 11.1 (7.3 to 16.6) | 11.4 (7.7 to 16.8) | 6.6 (4.5 to 9.8) | 8.5 (5.5 to 13.2) |
| S flexneri 3a Ab IgG, Day 113 | 25.7 (17.3 to 38.3) | 18.4 (12.2 to 27.7) | 16.0 (11.2 to 22.9) | 7.7 (5.2 to 11.5) |
| S flexneri 3a Ab IgG, Day 253 | 13.5 (9.8 to 18.7) | 8.8 (6.6 to 11.8) | 9.6 (6.9 to 13.2) | 10.7 (7.4 to 15.5) |
| S flexneri 3a Ab IgG, Day 281 | 45.7 (34.0 to 61.5) | 28.1 (21.1 to 37.4) | 36.3 (27.0 to 48.8) | 10.9 (7.4 to 16.1) |
| Participants | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| Day 1 | 1 | 0 | 5 |
| Day 15 | 22 | 19 | 4 |
| Day 29 | 22 | 18 | 4 |
| Day 85 | 17 | — | — |
| Day 169 | — | 14 | — |
| Day 85/169 | — | — | 3 |
| Day 113 | 21 | — | — |
| Day 197 | — | 22 | — |
| Day 113/197 | — | — | 3 |
| Participants | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| Day 1 | 7 | 5 |
| Day 29 | 10 | 5 |
| Day 85 | 10 | 6 |
| Day 113 | 10 | 5 |
| Participants | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| Day 1 | 2 | 4 | 3 |
| Day 29 | 7 | 6 | 2 |
| Day 85 | 7 | 6 | 3 |
| Day 113 | 7 | 6 | 5 |
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| Day 1 | 0 | 0 | 0 | 0 |
| Day 29 | 0 | 0 | 0 | 0 |
| Day 85 | 0 | 1 | 0 | 0 |
| Day 113 | 6 | 6 | 5 | 0 |
| Day 253 | 4 | 2 | 3 | 0 |
| Day 281 | 6 | 6 | 6 | 0 |
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| Day 1 | 1 | 0 | 2 | 1 |
| Day 29 | 10 | 11 | 12 | 0 |
| Day 85 | 9 | 9 | 6 | 1 |
| Day 113 | 51 | 52 | 57 | 2 |
| Day 253 | 42 | 48 | 49 | 8 |
| Day 281 | 61 | 61 | 67 | 8 |
| Participants | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| Day 1 | 1 | 0 | 2 |
| Day 15 | 13 | 11 | 2 |
| Day 29 | 12 | 11 | 2 |
| Day 85 | 12 | — | — |
| Day 169 | — | 9 | — |
| Day 85/169 | — | — | 2 |
| Day 113 | 11 | — | — |
| Day 197 | — | 10 | — |
| Day 113/197 | — | — | 2 |
| Participants | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| Day 1 | 2 | 3 |
| Day 29 | 10 | 3 |
| Day 85 | 10 | 3 |
| Day 113 | 10 | 2 |
| Participants | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| Day 1 | 0 | 1 | 1 |
| Day 29 | 7 | 6 | 0 |
| Day 85 | 7 | 6 | 1 |
| Day 113 | 7 | 6 | 3 |
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| Day 1 | 0 | 0 | 0 | 0 |
| Day 29 | 0 | 0 | 0 | 0 |
| Day 85 | 0 | 0 | 0 | 0 |
| Day 113 | 5 | 3 | 3 | 0 |
| Day 253 | 3 | 0 | 0 | 0 |
| Day 281 | 5 | 3 | 2 | 0 |
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| Day 1 | 1 | 0 | 2 | 0 |
| Day 29 | 2 | 0 | 2 | 0 |
| Day 85 | 2 | 2 | 1 | 1 |
| Day 113 | 38 | 36 | 36 | 1 |
| Day 253 | 18 | 20 | 28 | 2 |
| Day 281 | 40 | 45 | 47 | 2 |
| Participants | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group |
|---|---|---|---|
| S sonnei Ab IgG, Day 15 compared to Day 1 | 25 | 27 | 0 |
| S sonnei Ab IgG, Day 29 compared to Day 1 | 26 | 26 | 0 |
| S sonnei Ab IgG, Day 85 compared to Day 1 | 22 | — | — |
| S sonnei Ab IgG, Day 113 compared to Day 1 | 22 | — | — |
| S sonnei Ab IgG, Day 113 compared to Day 85 | 0 | — | — |
| S sonnei Ab IgG, Day 169 compared to Day 1 | — | 21 | — |
| S sonnei Ab IgG, Day 85/169 compared to Day 1 | — | — | 0 |
| S sonnei Ab IgG, Day 197 compared to Day 1 | — | 26 | — |
| S sonnei Ab IgG, Day 197 compared to Day 169 | — | 4 | — |
| S sonnei Ab IgG, Day 113/197 compared to Day 1 | — | — | 0 |
| S sonnei Ab IgG, Day 113/197 compared to Day 85/169 | — | — | 0 |
| S flexneri 1b Ab IgG, Day 15 compared to Day 1 | 17 | 16 | 0 |
| S flexneri 1b Ab IgG, Day 29 compared to Day 1 | 15 | 14 | 0 |
| S flexneri 1b Ab IgG, Day 85 compared to Day 1 | 7 | — | — |
| S flexneri 1b Ab IgG, Day 113 compared to Day 1 | 11 | — | — |
| S flexneri 1b Ab IgG, Day 113 compared to Day 85 | 2 | — | — |
| S flexneri 1b Ab IgG, Day 169 compared to Day 1 | — | 5 | — |
| S flexneri 1b Ab IgG, Day 85/169 compared to Day 1 | — | — | 0 |
| S flexneri 1b Ab IgG, Day 197 compared to Day 1 | — | 10 | — |
| S flexneri 1b Ab IgG, Day 197 compared to Day 169 | — | 1 | — |
| S flexneri 1b Ab IgG, Day 113/197 compared to Day 1 | — | — | 0 |
| S flexneri 1b Ab IgG, Day 113/197 compared to Day 85/169 | — | — | 0 |
| S flexneri 2a Ab IgG, Day 15 compared to Day 1 | 32 | 31 | 0 |
| S flexneri 2a Ab IgG, Day 29 compared to Day 1 | 30 | 31 | 0 |
| S flexneri 2a Ab IgG, Day 85 compared to Day 1 | 27 | — | — |
| S flexneri 2a Ab IgG, Day 113 compared to Day 1 | 26 | — | — |
| S flexneri 2a Ab IgG, Day 113 compared to Day 85 | 1 | — | — |
| S flexneri 2a Ab IgG, Day 169 compared to Day 1 | — | 31 | — |
| S flexneri 2a Ab IgG, Day 85/169 compared to Day 1 | — | — | 0 |
| S flexneri 2a Ab IgG, Day 197 compared to Day 1 | — | 32 | — |
| S flexneri 2a Ab IgG, Day 197 compared to Day 169 | — | 0 | — |
| S flexneri 2a Ab IgG, Day 113/197 compared to Day 1 | — | — | 0 |
| S flexneri 2a Ab IgG, Day 113/197 compared to Day 85/169 | — | — | 1 |
| S flexneri 3a Ab IgG, Day 15 compared to Day 1 | 12 | 17 | 0 |
| S flexneri 3a Ab IgG, Day 29 compared to Day 1 | 12 | 17 | 0 |
| S flexneri 3a Ab IgG, Day 85 compared to Day 1 | 2 | — | — |
| S flexneri 3a Ab IgG, Day 169 compared to Day 1 | — | 4 | — |
| S flexneri 3a Ab IgG, Day 85/169 compared to Day 1 | — | — | 0 |
| S flexneri 3a Ab IgG, Day 113 compared to Day 1 | 6 | — | — |
| S flexneri 3a Ab IgG, Day 113 compared to Day 85 | 3 | — | — |
| S flexneri 3a Ab IgG, Day 197 compared to Day 1 | — | 9 | — |
| S flexneri 3a Ab IgG, Day 197 compared to Day 169 | — | 1 | — |
| S flexneri 3a Ab IgG, Day 113/197 compared to Day 1 | — | — | 0 |
| S flexneri 3a Ab IgG, Day 113/197 compared to Day 85/169 | — | — | 0 |
| Participants | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control |
|---|---|---|
| S sonnei Ab IgG, Day 29 compared to Day 1 | 10 | 0 |
| S sonnei Ab IgG, Day 85 compared to Day 1 | 10 | 0 |
| S sonnei Ab IgG, Day 113 compared to Day 1 | 10 | 0 |
| S Sonnei Ab IgG, Day 113 compared to Day 85 | 0 | 0 |
| S flexneri 1b Ab IgG, Day 29 compared to Day 1 | 2 | 0 |
| S flexneri 1b Ab IgG, Day 85 compared to Day 1 | 1 | 0 |
| S flexneri 1b Ab IgG, Day 113 compared to Day 1 | 1 | 0 |
| S flexneri 1b Ab IgG, Day 113 compared to Day 85 | 0 | 0 |
| S flexneri 2a Ab IgG, Day 29 compared to Day 1 | 3 | 0 |
| S flexneri 2a Ab IgG, Day 85 compared to Day 1 | 2 | 0 |
| S flexneri 2a Ab IgG, Day 113 compared to Day 1 | 3 | 0 |
| S flexneri 2a Ab IgG, Day 113 compared to Day 85 | 0 | 0 |
| S flexneri 3a Ab IgG, Day 29 compared to Day 1 | 4 | 0 |
| S flexneri 3a Ab IgG, Day 85 compared to Day 1 | 2 | 0 |
| S flexneri 3a Ab IgG, Day 113 compared to Day 1 | 3 | 0 |
| S flexneri 3a Ab IgG, Day 113 compared to Day 85 | 0 | 0 |
| Participants | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control |
|---|---|---|---|
| S sonnei Ab IgG, Day 29 compared to Day 1 | 7 | 5 | 1 |
| S sonnei Ab IgG, Day 85 compared to Day 1 | 7 | 5 | 3 |
| S sonnei Ab IgG, Day 113 compared to Day 1 | 10 | 6 | 5 |
| S sonnei Ab IgG, Day 113 compared to Day 85 | 1 | 1 | 3 |
| S flexneri 1b Ab IgG, Day 29 compared to Day 1 | 2 | 4 | 1 |
| S flexneri 1b Ab IgG, Day 85 compared to Day 1 | 0 | 1 | 1 |
| S flexneri 1b Ab IgG, Day 113 compared to Day 1 | 2 | 3 | 1 |
| S flexneri 1b Ab IgG, Day 113 compared to Day 85 | 0 | 0 | 1 |
| S flexneri 2a Ab IgG, Day 29 compared to Day 1 | 6 | 6 | 0 |
| S flexneri 2a Ab IgG, Day 85 compared to Day 1 | 3 | 5 | 1 |
| S flexneri 2a Ab IgG, Day 113 compared to Day 1 | 7 | 10 | 0 |
| S flexneri 2a Ab IgG, Day 113 compared to Day 85 | 3 | 2 | 0 |
| S flexneri 3a Ab IgG, Day 29 compared to Day 1 | 0 | 3 | 0 |
| S flexneri 3a Ab IgG, Day 85 compared to Day 1 | 0 | 1 | 0 |
| S flexneri 3a Ab IgG, Day 113 compared to Day 1 | 1 | 3 | 1 |
| S flexneri 3a Ab IgG, Day 113 compared to Day 85 | 0 | 0 | 1 |
| Participants | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control |
|---|---|---|---|---|
| S sonnei Ab IgG, Day 29 compared to Day 1 | 2 | 0 | 1 | 0 |
| S sonnei Ab IgG, Day 85 compared to Day 1 | 2 | 1 | 3 | 0 |
| S sonnei Ab IgG, Day 113 compared to Day 1 | 8 | 8 | 9 | 0 |
| S sonnei Ab IgG, Day 113 compared to Day 85 | 7 | 6 | 7 | 0 |
| S sonnei Ab IgG, Day 253 compared to Day 1 | 8 | 6 | 6 | 0 |
| S sonnei Ab IgG, Day 281 compared to Day 1 | 9 | 7 | 9 | 0 |
| S sonnei Ab IgG, Day 281 compared to Day 253 | 3 | 2 | 2 | 0 |
| S flexneri 1b Ab IgG, Day 29 compared to Day 1 | 3 | 1 | 1 | 0 |
| S flexneri 1b Ab IgG, Day 85 compared to Day 1 | 1 | 0 | 0 | 3 |
| S flexneri 1b Ab IgG, Day 113 compared to Day 1 | 3 | 0 | 2 | 3 |
| S flexneri 1b Ab IgG, Day 113 compared to Day 85 | 2 | 0 | 2 | 1 |
| S flexneri 1b Ab IgG, Day 253 compared to Day 1 | 1 | 0 | 1 | 5 |
| S flexneri 1b Ab IgG, Day 281 compared to Day 1 | 3 | 2 | 4 | 3 |
| S flexneri 1b Ab IgG, Day 281 compared to Day 253 | 1 | 1 | 2 | 0 |
| S flexneri 2a Ab IgG, Day 29 compared to Day 1 | 6 | 5 | 5 | 3 |
| S flexneri 2a Ab IgG, Day 85 compared to Day 1 | 4 | 3 | 3 | 3 |
| S flexneri 2a Ab IgG, Day 113 compared to Day 1 | 8 | 6 | 9 | 6 |
| S flexneri 2a Ab IgG, Day 113 compared to Day 85 | 1 | 4 | 5 | 3 |
| S flexneri 2a Ab IgG, Day 253 compared to Day 1 | 2 | 2 | 4 | 8 |
| S flexneri 2a Ab IgG, Day 281 compared to Day 1 | 8 | 7 | 7 | 7 |
| S flexneri 2a Ab IgG, Day 281 compared to Day 253 | 6 | 5 | 7 | 0 |
| S flexneri 3a Ab IgG, Day 29 compared to Day 1 | 4 | 2 | 0 | 2 |
| S flexneri 3a Ab IgG, Day 85 compared to Day 1 | 0 | 0 | 0 | 2 |
| S flexneri 3a Ab IgG, Day 113 compared to Day 1 | 3 | 1 | 0 | 1 |
| S flexneri 3a Ab IgG, Day 113 compared to Day 85 | 2 | 0 | 0 | 0 |
| S flexneri 3a Ab IgG, Day 253 compared to Day 1 | 2 | 2 | 0 | 3 |
| S flexneri 3a Ab IgG, Day 281 compared to Day 1 | 4 | 4 | 3 | 2 |
| S flexneri 3a Ab IgG, Day 281 compared to Day 253 | 3 | 1 | 3 | 1 |
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| S sonnei Ab IgG, Day 29 compared to Day 1 | 20 | 30 | 24 | 0 |
| S sonnei Ab IgG, Day 85 compared to Day 1 | 28 | 29 | 20 | 3 |
| S sonnei Ab IgG, Day 113 compared to Day 1 | 57 | 61 | 64 | 2 |
| S sonnei Ab IgG, Day 113 compared to Day 85 | 19 | 15 | 15 | 0 |
| S sonnei Ab IgG, Day 253 compared to Day 1 | 53 | 60 | 58 | 11 |
| S sonnei Ab IgG, Day 281 compared to Day 1 | 62 | 62 | 69 | 12 |
| S sonnei Ab IgG, Day 281 compared to Day 253 | 7 | 4 | 8 | 1 |
| S flexneri 1b Ab IgG, Day 29 compared to Day 1 | 22 | 24 | 18 | 3 |
| S flexneri 1b Ab IgG, Day 85 compared to Day 1 | 7 | 9 | 5 | 3 |
| S flexneri 1b Ab IgG, Day 113 compared to Day 1 | 17 | 13 | 11 | 1 |
| S flexneri 1b Ab IgG, Day 113 compared to Day 85 | 5 | 2 | 4 | 1 |
| S flexneri 1b Ab IgG, Day 253 compared to Day 1 | 10 | 3 | 4 | 12 |
| S flexneri 1b Ab IgG, Day 281 compared to Day 1 | 31 | 29 | 25 | 13 |
| S flexneri 1b Ab IgG, Day 281 compared to Day 253 | 19 | 15 | 13 | 1 |
| S flexneri 2a Ab IgG, Day 29 compared to Day 1 | 50 | 52 | 49 | 3 |
| S flexneri 2a Ab IgG, Day 85 compared to Day 1 | 22 | 24 | 24 | 8 |
| S flexneri 2a Ab IgG, Day 113 compared to Day 1 | 54 | 52 | 58 | 7 |
| S flexneri 2a Ab IgG, Day 113 compared to Day 85 | 39 | 36 | 42 | 3 |
| S flexneri 2a Ab IgG, Day 253 compared to Day 1 | 30 | 27 | 29 | 18 |
| S flexneri 2a Ab IgG, Day 281 compared to Day 1 | 59 | 59 | 65 | 16 |
| S flexneri 2a Ab IgG, Day 281 compared to Day 253 | 41 | 48 | 52 | 3 |
| S flexneri 3a Ab IgG, Day 29 compared to Day 1 | 15 | 25 | 14 | 3 |
| S flexneri 3a Ab IgG, Day 85 compared to Day 1 | 13 | 20 | 9 | 10 |
| S flexneri 3a Ab IgG, Day 113 compared to Day 1 | 26 | 25 | 22 | 9 |
| S flexneri 3a Ab IgG, Day 113 compared to Day 85 | 16 | 8 | 14 | 2 |
| S flexneri 3a Ab IgG, Day 253 compared to Day 1 | 17 | 15 | 16 | 18 |
| S flexneri 3a Ab IgG, Day 281 compared to Day 1 | 36 | 36 | 41 | 17 |
| S flexneri 3a Ab IgG, Day 281 compared to Day 253 | 22 | 18 | 30 | 2 |
| mIU/mL | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| Day 1 | 26.2 (23.8 to 28.9) | 25.4 (24.6 to 26.1) | 25 (25 to 25) | 26.2 (24.5 to 28.1) |
| Day 281 | 1204.4 (1043.2 to 1390.6) | 1099.7 (957.2 to 1263.4) | 1142.5 (983 to 1327.9) | 971.4 (793.2 to 1189.7) |
| mIU/mL | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| Day 1 | 1.2 (1 to 1.4) | 1 (1 to 1) | 1.1 (1 to 1.3) | 1.1 (1 to 1.1) |
| Day 281 | 138.2 (124.7 to 153.1) | 110.3 (99.6 to 122.1) | 116.4 (105.1 to 129) | 107.1 (89.9 to 127.5) |
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| >= 150 mIU/mL, Day 281 | 66 | 64 | 71 | 68 |
| >= 200 mIU/mL, Day 281 | 66 | 64 | 71 | 67 |
| Participants | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|
| >= 4 IU/mL Day 281 | 66 | 64 | 71 | 68 |
| >= 10 IU/mL Day 281 | 66 | 64 | 71 | 68 |
Collected over Solicited AEs were collected within 7 days and unsolicited AEs within 28 days after any intervention (administered on Day (D) 1 and D85 for Stage 1 adults, Stage 2 adults and children and D1, D85 and D253 for Stage 2 infants). SAEs and all-cause mortality: from Day (D) 1 to D113/D197 for stage 1, from D1 to D113 for Stage 2 adults & children, from D1 to D281 for Stage 2 infants.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | 0/34 (0%) | 0/34 (0%) | 33/34 (97.1%) |
| Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | 0/34 (0%) | 1/34 (2.9%) | 33/34 (97.1%) |
| Stage 1 Adults: Placebo Group | 0/34 (0%) | 0/34 (0%) | 32/34 (94.1%) |
| Stage 2 Adults: altSonflex1-2-3 High Dose | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Stage 2 Adults: Control | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Stage 2 Children: altSonflex1-2-3 Medium Dose | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Stage 2 Children: altSonflex1-2-3 High Dose | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Stage 2 Children: Control | 0/20 (0%) | 0/20 (0%) | 12/20 (60%) |
| Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Stage 2 Infants Safety Cohort: Control | 0/30 (0%) | 1/30 (3.3%) | 26/30 (86.7%) |
| Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | 0/82 (0%) | 2/82 (2.4%) | 77/82 (93.9%) |
| Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | 1/81 (1.2%) | 1/81 (1.2%) | 74/81 (91.4%) |
| Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | 0/83 (0%) | 4/83 (4.8%) | 80/83 (96.4%) |
| Stage 2 Infants Dose-finding Cohort: Control | 0/82 (0%) | 1/82 (1.2%) | 69/82 (84.1%) |
| Event | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/34 | 0/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 0/10 | 0/10 | 1/30 | 1/82 | 0/81 | 1/83 | 0/82 |
| FaecalomaGastrointestinal disorders | 0/34 | 1/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 0/10 | 0/10 | 0/30 | 0/82 | 0/81 | 0/83 | 0/82 |
| GastroenteritisInfections and infestations | 0/34 | 0/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 0/10 | 0/10 | 0/30 | 0/82 | 1/81 | 1/83 | 0/82 |
| EpilepsyNervous system disorders | 0/34 | 0/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 0/10 | 0/10 | 0/30 | 1/82 | 0/81 | 0/83 | 0/82 |
| Infantile spasmsNervous system disorders | 0/34 | 0/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 0/10 | 0/10 | 0/30 | 0/82 | 0/81 | 0/83 | 1/82 |
| StomatitisGastrointestinal disorders | 0/34 | 0/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 0/10 | 0/10 | 0/30 | 0/82 | 0/81 | 1/83 | 0/82 |
| Oral candidiasisInfections and infestations | 0/34 | 0/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 0/10 | 0/10 | 0/30 | 0/82 | 0/81 | 1/83 | 0/82 |
| Thermal burnInjury, poisoning and procedural complications | 0/34 | 0/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 0/10 | 0/10 | 0/30 | 0/82 | 0/81 | 1/83 | 0/82 |
| Event | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Administration site painGeneral disorders | 33/34 | 33/34 | 20/34 | 7/10 | 4/10 | 7/10 | 3/10 | 3/20 | 4/10 | 5/10 | 7/10 | 7/30 | 49/82 | 57/81 | 58/83 | 35/82 |
| Administration site erythemaGeneral disorders | 5/34 | 8/34 | 1/34 | 0/10 | 0/10 | 1/10 | 1/10 | 0/20 | 0/10 | 1/10 | 6/10 | 1/30 | 20/82 | 21/81 | 32/83 | 14/82 |
| Administration site swellingGeneral disorders | 5/34 | 9/34 | 0/34 | 0/10 | 0/10 | 1/10 | 1/10 | 0/20 | 1/10 | 2/10 | 5/10 | 5/30 | 30/82 | 32/81 | 34/83 | 20/82 |
| PyrexiaGeneral disorders | 2/34 | 1/34 | 1/34 | 0/10 | 0/10 | 2/10 | 2/10 | 3/20 | 1/10 | 3/10 | 5/10 | 9/30 | 38/82 | 28/81 | 37/83 | 18/82 |
| RhinitisInfections and infestations | 0/34 | 2/34 | 0/34 | 0/10 | 0/10 | 1/10 | 0/10 | 2/20 | 2/10 | 2/10 | 4/10 | 6/30 | 7/82 | 9/81 | 6/83 | 13/82 |
| HeadacheNervous system disorders | 12/34 | 10/34 | 8/34 | 3/10 | 1/10 | 0/10 | 0/10 | 0/20 | 0/10 | 0/10 | 0/10 | 0/30 | 0/82 | 0/81 | 0/83 | 0/82 |
| Upper respiratory tract infectionInfections and infestations | 2/34 | 0/34 | 2/34 | 0/10 | 1/10 | 2/10 | 0/10 | 1/20 | 2/10 | 1/10 | 2/10 | 8/30 | 17/82 | 19/81 | 18/83 | 21/82 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/34 | 0/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 2/10 | 1/10 | 0/30 | 0/82 | 0/81 | 0/83 | 0/82 |
| ThrombocytosisBlood and lymphatic system disorders | 0/34 | 0/34 | 0/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 2/10 | 0/10 | 0/30 | 0/82 | 0/81 | 0/83 | 0/82 |
| GastroenteritisInfections and infestations | 0/34 | 1/34 | 1/34 | 0/10 | 0/10 | 0/10 | 0/10 | 0/20 | 0/10 | 1/10 | 2/10 | 0/30 | 3/82 | 8/81 | 11/83 | 8/82 |
| Age, Categorical(Participants) | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 10 | 10 | 20 | 10 | 10 | 10 | 30 | 82 | 81 | 83 | 82 | 428 |
| Between 18 and 65 years | 34 | 34 | 34 | 10 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 122 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 28 | 27 | 27 | 6 | 6 | 4 | 4 | 11 | 7 | 5 | 4 | 16 | 32 | 43 | 41 | 49 | 310 |
| Male | 6 | 7 | 7 | 4 | 4 | 6 | 6 | 9 | 3 | 5 | 6 | 14 | 50 | 38 | 42 | 33 | 240 |
| Race/Ethnicity, Customized(Participants) | Stage 1 Adults: altSonflex1-2-3 High Dose Group 1 | Stage 1 Adults: altSonflex1-2-3 High Dose Group 2 | Stage 1 Adults: Placebo Group | Stage 2 Adults: altSonflex1-2-3 High Dose | Stage 2 Adults: Control | Stage 2 Children: altSonflex1-2-3 Medium Dose | Stage 2 Children: altSonflex1-2-3 High Dose | Stage 2 Children: Control | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Safety Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Safety Cohort: Control | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Low Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 Medium Dose | Stage 2 Infants Dose-finding Cohort: altSonflex1-2-3 High Dose | Stage 2 Infants Dose-finding Cohort: Control | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BLACK OR AFRICAN AMERICAN | 0 | 0 | 0 | 10 | 10 | 10 | 10 | 20 | 10 | 10 | 10 | 30 | 82 | 81 | 83 | 82 | 448 |
| WHITE | 34 | 34 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 102 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Oct 2021 to primary completion in Jun 2025, 44 months.
Results were first posted in Jun 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.